U.S. Application No. 10/030,262

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re application of:

Bruno CRIERE et al.

Atty. Dck. No. 017751-030

Serial No.: 10/030,262

Group Art Unit: 1615

Filed: April 17, 2002

Examiner: Channavajjala, Lakshi Sarada

For:

OCT 2 1 2005

PHARMACEUTICAL COMPOSITION CONTAINING FENOFIBRATE AND THE

PREPARATION METHOD

DECLARATION UNDER 37 C.F.R. § 1.132

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

- I, George Bobotas, Ph.D., hereby declare and affirm that:
- 1. I am employed as Vice President, Scientific Affairs at Reliant Pharmaceuticals, Inc., the exclusive licensee of the above-identified patent application.
- 2. I have over 25 years of clinical and scientific affairs experience with leading pharmaceutical and clinical development organizations. I have extensive research experience and am a member of numerous professional organizations, including the American Association for the Advancement of Science, the New York Academy of Science, and the American Chemical Society. I previously worked as the Executive Director, CNS Center for Covance Inc., where I managed the operational, scientific, and financial aspects of the Center. Prior to Covance, I led Scientific Affairs and Licensing for Somerset Pharmaceuticals, Inc., New Product Licensing and Evaluation for Mylan Laboratories Inc., and

biochemistry and pharmacokinetics for Forest Laboratories, Inc. In addition, I am a listed inventor on five issued U.S. Patents and numerous U.S. patent applications. I hold a Doctorate in Biochemistry from City University of New York and Masters Degrees in Biochemistry from the City University of New York and in Physical Chemistry from Smith College.

3. I am submitting this Declaration in support of the referenced patent application. I am familiar with the subject matter described and claimed in the application. I am also familiar with U.S. Patent No. 4,895,726 ("the '726 patent") and U.S. Patent No. 6,074,670 ("the '670 patent").

Comparison Of Formulations Covered By The Present Invention To Commercial Embodiments Of The '726 Patent And The '670 Patent

4. I designed and supervised the performance of a comparison between pharmaceutical formulations covered by the present invention and commercial embodiments of the '726 and '670 patents. Several sets of comparative data are presented in this Section (Studies A, B and C). The data show that, with a healthy low-fat diet, on a per-milligram basis, fenofibrate formulations according to the present invention are more bioavailable than the commercial fenofibrate formulations covered by the '726 patent and/or the '670 patent. The data also show that by increasing the percentage of fenofibrate and reducing the percentage of polymer (in comparison to the amounts disclosed in the '670 patent), we can achieve a substantial increase in fenofibrate bioavailability, which, in turn, permits a substantial reduction in fenofibrate dosage while providing the same therapeutic effect.

Study A

5. Study Design – A randomized, single-dose, crossover study to assess the

relative bioavailability of 130 mg ANTARA® fenofibrate capsules¹ versus 200 mg TRICOR® fenofibrate capsules² in healthy adult subjects following consumption of a therapeutic lifestyle change (TLC) meal. 29 healthy adult males and females completed the study. Following randomization, subjects received a single dose of medication at the beginning of each treatment period. After completion of the first period, subjects crossed over. A washout period of at least 14 days occurred between treatment periods. Blood samples for the determination of plasma fenofibric acid were drawn prior to dosing and periodically up to 168 hours after dosing.

6. Pharmacokinetic Results – The following TABLE 1 summarizes selected pharmacokinetic parameters for fenofibric acid following a TLC meal (arithmetic mean (± SD)) and the ratios of least square means for 1n-transformed data (with 90% confidence intervals):

TABLE 1

Parameter	Treatment A: 130 mg ANTARA® capsules	Treatment B: 200 mg TRICOR® capsules	Ratio of LSM A/B% (90% CI)
AUC _{0-∞} (ng·h/ml)	132,387 (±40,251)	162,332 (±45,509)	83.2 (75.9-91.3)
C _{max} (ng/ml)	7,565 (±1,593)	7,554 (±2,934)	105.7 (90.5-123.5)
T _{max} (h)	4.21 (±0.632)	4.58 (±0.508)	N/A

7. The following TABLE 2 compares the relative bioavailability of the 130 mg fenofibrate formulation covered by the present invention, versus the 200 mg TRICOR® capsules covered by the '726 patent, on a per-milligram basis by

¹ This product, distributed by Reliant Pharmaceuticals, Inc., is covered by the present invention. The exact formulation of ANTARA® is a trade secret.

² Abbott Laboratories, Inc., the distributor of 200 mg TRICOR® fenofibrate capsules, listed the '726 patent in the Food and Drug Administration's "Approved Drug Products With Therapeutic Equivalence Evaluations" (also known as the "Orange Book") as covering the product.

Declaration under 37 C.F.R. § 1.132 U.S. Application No. 10/030,262

comparing AUC_{0-x}

TABLE 2

1		Mean AUC _{0-∞} per mg fenofibrate	% increase in bioavailability per mg
130 mg ANTARA [®] capsules	132,387	1,018	25.5%
200 mg TRICOR [®] capsules	162,332	811	

8. Conclusions – This single dose study compared the bioavailability of 130 mg ANTARA® fenofibrate capsules covered by the present invention, versus 200 mg TRICOR® fenofibrate capsules covered by the '726 patent, in subjects following consumption of a TLC meal. The formulation according to the present invention (130 mg ANTARA® capsules) showed a 25.5% increase in bioavailability on a per-milligram basis, as compared to the formulation covered by the '726 patent (200 mg TRICOR® capsules).

Study B

9. Study Design – A randomized, multiple-dose, crossover study to assess the relative bioavailability of 130 mg ANTARA® fenofibrate capsules versus 200 mg TRICOR® fenofibrate capsules at steady state in healthy adult subjects on a therapeutic lifestyle change (TLC) diet. 26 healthy adult males and females completed the study. Following randomization, subjects received a single dose of medication daily for 7 days. After completion of the first period, subjects crossed over to the alternate treatment for 7 days. A washout period of at least 14 days occurred between treatment periods. Blood samples for the determination of plasma fenofibric acid were drawn on day 1 prior to the first dosing and at steady state on day 7 of each treatment period, just prior to

administration of the final dose of the study drug (time 0) and at 1, 2, 3, 4, 4.5, 5, 5.5, 6, 7, 8, 10, 12, 16 and 24 hours postdose. Trough blood samples were taken on days 4, 5, 6, 7 and 8 of each treatment period to establish whether steady state had been reached.

10. Pharmacokinetic Results – The following TABLE 3 summarizes selected pharmacokinetic parameters for fenofibric acid at steady state following a TLC meal (arithmetic mean (± SD)) and the ratios of least square means for 1n-transformed data (with 90% confidence intervals):

TABLE 3

Parameter	Treatment A: 130 mg ANTARA® capsules	Treatment B: 200 mg TRICOR® capsules	Ratio of LSM A/B% (90% CI)
AUC _{τ, ss} (ng·h/ml)	182,889 (±53,669)	204,988 (±50,945)	88.4 (84.0-93.0)
C _{max, ss} (ng/ml)	12,664 (±2,685)	13,810 (±2,781)	91.7 (85.1-98.7)
T _{max, ss} (h)	4.89 (±0.978)	5.34 (±1.281)	N/A

11. The following TABLE 4 compares the relative bioavailability of the 130 mg fenofibrate formulation covered by the present invention, versus the 200 mg TRICOR® capsules covered by the '726 patent, on a per-milligram basis by comparing AUC_{7. ss}:

TABLE 4

Treatment	Mean AUC _{τ, ss}	Mean AUC $_{\tau, ss}$ per mg fenofibrate	% increase in bioavailability per mg
130 mg ANTARA [®] capsules	182,889	1,406	37.3%

Declaration under 37 C.F.R. § 1.132 U.S. Application No. 10/030,262

200 mg	204,988	1,024		
TRICOR®			1 .	
capsules				

12. Conclusions – This multiple-dose study compared the bioavailability of 130 mg ANTARA® fenofibrate capsules covered by the present invention, versus 200 mg TRICOR® fenofibrate capsules covered by the '726 patent, at steady state in subjects on a TLC diet. The formulation according to the present invention (130 mg ANTARA® capsules) showed a 37.3% increase in bioavailability on a permilligram basis, as compared to the formulation covered by the '726 patent (200 mg TRICOR® capsules).

Study C

- 13. Study Design A randomized, single-dose, crossover study to assess the relative bioavailability of 120 mg and 144 mg fenofibrate capsules covered by the present invention, versus 160 mg TRICOR® fenofibrate tablets³ in healthy adult subjects following consumption of a National Cholesterol Education Program (NCEP) Step 1 low-fat diet. 15 healthy adult males completed the study. Following randomization, subjects received a single dose of medication at the beginning of each treatment period. After completion of each period, subjects crossed over. A washout period of at least 7 days occurred between treatment periods. Blood samples for the determination of plasma fenofibric acid were drawn prior to dosing and at 1, 2, 3, 4, 4.5, 5, 5.5, 6, 7, 8, 10, 12, 16, 24, 36, 48, 72 and 96 hours after dosing.
- 14. Pharmacokinetic Results The following TABLE 5 summarizes selected pharmacokinetic parameters for fenofibric acid following a NCEP Step 1 low-fat

³ Abbott Laboratories, Inc., the distributor of 160 mg TRICOR® fenofibrate tablets, listed the '670 patent in the FDA's Orange Book as covering the product. (The '726 patent is also listed; however, the '726 patent claims only cover capsules, not tablets, and therefore the '726 patent is not relevant to this product.)

Declaration under 37 C.F.R. § 1.132 U.S. Application No. 10/030,262

diet (arithmetic mean (± SD)) and the ratios of least square means for 1n-transformed data (with 90% confidence intervals):

TABLE 5

Parameter	Treatment A: 120 mg fenofibrate capsules	Treatment B: 144 mg fenofibrate capsules	Treatment C: 160 mg TRICOR® tablets	Ratio of LSM A/C% (90% CI)	Ratio of LSM B/C% (90% CI)
AUC _{0-∞} (ng·h/ml)	115,452 (±18,889)	132,467 (±22,929)	128,305 (±30,672)	91.6 (86.8-96.7)	105.1 (99.6- 110.8)
C _{max} (ng/ml)	7,669 (±1,234)	8,750 (±1387)	6,708 (±1,488)	115.1 (104.1- 127.2)	131.3 (118.8- 145.1)
T _{max} (h)	4.07 (±0.863)	4.30 (±0.702)	3.93 (±0.728)	N/A	N/A

15. The following TABLE 6 compares the relative bioavailability of the 120 mg and 144 mg fenofibrate formulations covered by the present invention, versus the 160 mg TRICOR[®] tablets covered by the '670 patent, on a per-milligram basis by comparing AUC_{0-∞}:

TABLE 6

Treatment	Mean AUC₀-∞	Mean AUC _{0-∞} per mg fenofibrate	% increase in bioavailability per mg
120 mg fenofibrate capsules	115,452	962	20.0%
144 mg fenofibrate capsules	132,467	920	14.7%
160 mg TRICOR [®] tablets	128,305	802	

16. Conclusions – This single dose study compared the bioavailability of 120 mg and 144 mg fenofibrate capsules covered by the present invention, versus 160 mg TRICOR® fenofibrate tablets covered by the '670 patent, in subjects following consumption of a NCEP Step 1 low-fat diet. The formulations according to the present invention (120 mg and 144 mg capsules) showed a 20.0% and 14.7% increase, respectively, in bioavailability on a per-milligram basis, as compared to the formulation covered by the '670 patent (160 mg TRICOR® tablets).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent(s) issuing therefrom.

Date:

George Bobotas

List of Attachments

- A. Product Insert Lipidil®
- B. Product insert Tricor® (67, 134 & 200 mg)
- C. 2002 Orange Book listing for Tricor®
- D. Product insert Tricor® (54 mg and 160 mg)
- E. Product insert for Tricor® (48 & 145 mg)
- F. Product insert for Antara®

LIPIDIL®
(Fenofibrate Capsules)

DESCRIPTION

LIPIDIL (fenofibrate capsules of a lipid regulating agent. It is available as capsules for oral administration. Each capsule contains 100 mg of fenofibrate. Each capsule also contains lactose, NF magnesium stearate, NF, and pregelatinized starch, NF. The chemical name is 2-(4-(4-chlorobenzoy) phenoxy)-2-methylpropanoic and 1 methylethyl ester with the following structural formula:

The empirical formula is $C_{20}H_{20}\Box 10_4$ and the molecular weight is 360.84; fenofibrate is insoluble in water. The melting point is 77-82°C ienofibrate is a white solid which is stable under ordinary conditions

CLINICAL PHARMACOUCH 1

The effects of LIPIDIL 100 mg nd on serum triglycerides were studied in two randomized, double-blind clinical trials¹. 147 hypertriglyceridemic patients (Types IV and V) were treated for eight weeks under protocols that differed only in that one entered patients with baseline triglyceride (TG) levels of 500 to 1500 mg/dL, and the other TC levels of 250 to 500 mg/dL. In patients with hypertriglyceridemia and normal cholesterolemia with 0° without hyperchylomicronemia (Type IV/V hyperlipidemia), treatment with LIPIDIL decreased primarily very low density lipoprotein (VLDL) triglycerides and VLDI cholesterol. Treatment of patients with Type IV hyperlipoproteinemia and elevated triglycerides often results in an increase of low density lipoprotein (LDL) cholesterol as seen in the following table of changes seen at the end of treatment in patients with triglycerides of 500 to 1500 mg/dL.

Changes in Lipid and Lipoprotein Determinations. Type IV/V Patients

	I. acepo		LIPIDIL (100	mg tid)		
-	Basen (f °Aea ⊕ £	% Change	Baseline Mean (mg/dL)	% Change	Net Difference (of %)	
Triglycerides Total VLDL	÷ ,	+ 7 + 19	726 543	- 55 31	- 62 - 70	
Cholesterol Total HDL LDL VLDL	2° 10' 10'	0 + 5 - 4 + 11	261 30 103 126	14 + 23 + 45 - 49	- 14 + 18 + 49 - 60	

The mechanism of action of LIPIDIL has not been clearly established in man. Fenofibric acid, the active metabolite of fenofibrate, lowers plasma triglycerides apparently by inhibiting triglyceride synthesis, resulting in a reduction of VLDL released into the circulation, and also by stimulating the catabolism of triglyceride-rich lipoprotein i.e., VLDL). LIPIDIL also reduces serum uric acid levels in hyperunicemic and normal individuals by increasing the uninary excretion of uric acid.

Fenofibrate is well absorbed from the gastrointestinal tract. Following oral administration in healthy volunteers, approximately 60% or a single radiolabelled 300 mg dose of fenofibrate appeared in the unner primarily as fenofibric acid and its glucuronate conjugate, and 25% was excreted in the feces. Peak plasma levels of fenofibric acid occur within 6 to 8 hours after administration, and the compound is eliminated with a half-life of 20 nours. Serum protein binding was approximately 99% in normal and hyperlipidemic subjects. In healthy volunteers, steady-state plasma levels of fenofibric acid were shown to be achieved within 5 days of dosing with 100 mg/day, and did not demonstrate accumulation across time following multiple dose administration. In elderly volunteers 77-87 years of age, the oral clearance of fenofibric acid following a single oral dose of 100 mg was 1.2 L/h, which compares with 1.1 L/h in young adults. This indicates that a similar dosage regimen can be used in the elderly, without increasing accumulation of the drug or metabolites.

In a study in patients with severe renal impairment (creatinine clearance < 50 ml/min), the rate of clearance of fenofibric acic was greatly reduced, and the compound accumulated during chronic dosage

However, in patients having moderate renal impairment (creatinine clearance of 50 to 90 ml/min) the oral clearance and the oral volume of distribution of fenofibric acid are increased compared to healthy adults. Therefore, the dosage of LIPIDIL should be reduced in patients who have severe renal impairment, while no modification of dosage is required in patients having moderate renal impairment.

INDICATIONS AND USAGE

LIPIDIL (fenofibrate capsules) is indicated as adjunctive therapy to diet for treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who are at risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycarides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronomia thereby obviating the need for pharmacologic intervention. LIPIDIL therapy may be considered for these subjects with triglyouride elevations between 1000 and 2000 mg/dL who have a history of pancrealitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronomia, but the influence of LIPIDIL therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hypeslipeproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia2.

The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like this side diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia.

The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet.

Because the benefit/risk ratio of LIPIDIL (fenofibrate) has not been established in clinical trials of primary or secondary prevention to reduce the risk of developing coronary heart disease, LIPIDIL is not indicated for such use. (See WARNINGS and PRECAUTIONS).

CONTRAINDICATIONS

- 1. Hepatic or severe renal dysfunction, including primary biliary cirrhosis, and patients with unexplained persistent liver function abnormality.
- Preexisting gulfbladder disease (see WARNINGS).
- 3. Hypersensitivity to fenofibrate.

WARNINGS

1. Because of chemical, pharmasological, and clinical similarities between LIPIDIL (ferofibeate), Atromid-S (clofibrate), and Lapid (granfibrate)), the adverse findings in 4 large randomized, placebo-controlled clinical studies with these other fibrate drugs may also apply to LIPIDIL. In the first of these studies, the Coronary Drug Project, 1000 subjects with previous myeanedial infarction were treated for 5 years with clofibrate. There was no difference in mortality between the clofibrate-treated subjects and 2000 placebo-treated subjects, but twice as many clofibrate-treated subjects developed chelcithiasis and cholocystitis requiring surgery. In a study, conducted by the World Health Organization (WHO), 5000 subjects without known coronary heart disease were treated with clofibrate for 5 years and followed 1 year beyond. There was a statistically significant, 44% higher age-adjusted total mortality in the clofibrate-treated than in a comparable placebo-treated control group during the trial period. The excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholocystoctomy complications, and pancreatitis. The higher risk of clofibrate-treated subjects for galibladder disease was confirmed.

During the 5 year primary prevention component of the Helsinki Heart Study involving 4081 in middle-agad males treated with either gamfibronil or placebo, and the 3.5 year open extension, total mortality was 22% higher in the original gamfibronil randomization group (p=0.19, 95% confidence interval for relative risk G:P=0.91-1.64). Cancer deaths trended higher in the gamfibronil group (p=0.11), while cancers (excluding basal cell carcinoma) were diagnosed in 2.5% of patients in both treatment groups. Because of the more limited size of the Helsinki

Heart Study, the relative risk of death from any cause did not differ statistically from the relative risk of 1.29 clofibrate/placebo observed at the 9 year follow-up of the WHO study. Similarly, the numerical excess of guilbladder surgeries in the gumfibrozil group (0.9% vs. 0.5% with placebo) did not differ statistically from the excess observed in the clofibrate group compared to placebo in the WHO study.

The secondary prevention component of the Helsinki Heart Study involved 628 middle-aged males excluded from the primary prevention study because of known or suspected coronary heart disease and treated with either gemfibrozil or placebo for 5 years. Cardiac deaths trended higher in the gemfibrozil group (17/311 vs. 8/317 placebo patients, p=0.06, hazard ratio 2.2, 95% confidence interval for hazard ratio = 0.94-5.05). Galibladder surgery was more frequent in the gemfibrozil group (1.9% vs. 0.3%, p=0.07), as was appendectomy (6 cases on gemfibrozil vs. 0 on placebo, p=0.029).

Liver Function: Femolihente use at doses of 200 to 300 mg/day is associated with significant increases in series transmisses [AST (SGOT) or ALT (SPGT)]. Increases to > 3 times the upper limit of normal communication 6.3% of LIPIDIL-treated patients taking 200 to 300 mg/day in controlled multiple-dose trials lasting 8-24 weeks.

Patients with AST or ALT > 3x the Upper Normal Limits in Controlled Clinical Trials vs Penofibrate (200 to 300 mg/day)

	N	# Bvents	Events Rate
Control	336	4	1.2%
Fenofibrate	442	28	6.3%

When transaminase determinations were followed either after discontinuation of treatment or during continued transaminase determinations remained above normal limits was usually observed. However, the transaminase determinations remained above normal limits in 2 of the 28 patients (7.1%) at the end of follow-up off treatment. Fenofibrate hepatotoxicity appears to be dose-related. In an 8-week dose-ranging study the incidence of ALT or AST elevations at least three times the upper limit of normal was 13% in patients receiving 200 or 300 mg/day and was 0% in those receiving 100 or 50 mg/day, or placebo. Both hepatocellular and cholestatic hepatitis have been reported. In literature reports, hepatitis associated with fenofibrate has occurred after exposures of weeks to several years.

Regular periodic monitoring of liver function, including serum ALT (SGPT) should be performed

for the duration of therapy with LIPIDIL, and therapy discontinued if enzyme levels persist above three times the normal limit.

- 3. Cholelithiasis. A gallstone prevalence substudy of 450 Helsinki Heart Study participants showed a trend toward a greater prevalence of gallstones during the study within the gemfibrozil -treatment group. Penofibrate, like clofibrate and gemfibrosil, may increase cholesterol excretion into the bile, leading to cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated. LIPIDIL therapy should be discontinued if gallstones are found.
- 4. Concomitant Oral Anticoagulants. Caution should be exercised when anticoagulants are given in conjunction with LIPIDIL because of the potentiation of coumarin-type anticoagulants in prolonging the prothrombin time. The dosage of the anticoagulant should be reduced to maintain the prothrombin time at the desired level to prevent bleeding complications.* Frequent prothrombin determinations are advisable until it has been definitely determined that the prothrombin level has stabilized.
- 5. Concomitant therapy with LIPIDIL and HMG-CoA reductore inhibitors (such as lovastatin, preventatin, and simustatin). No data exists on this combined therapy. The association of the chemically and phasmacologically related nimiter compound gentilibroril and Mevacor® (lovastatin) has been associated with stub-domyulysis, masterdly elevated creatine kinese (CK) levels and myoglobinuria, leading in a high proportion of cases to acute renal failure.

In virtually all patients who have had an unsatiofactory lipid response to either drug alone, any potential lipid benealt of combined thompy with HMG CoA reductace inhibitous and LIPIDIL does not outweigh the risks of severe myspethy, shabdomyslysis, and acute remainfailure. The use of fibrates alone, including LIPIDIL, may occasionally be associated with myositis, myopathy, or shabdomyolysis. Patients receiving LIPIDIL and complaining of muscle pain, tenderness, or weakness should have prompt medical evaluation for myopathy, including serum creatine kinese level determination. If myopathy/myositis is suspected or diagnosed, LIPIDIL therapy should be stopped.

6. The effect of LIPIDIL on coronary heart disease morbidity and mortality and non-cardiovascular mortality has not been established. LIPIDIL should be administered only to those patients of described under INDICATIONS AND USAGE. If a significant reduction in fasting chylomicronemia does not occur, LIPIDIL should be discontinued.

Revised: November 12, 1993

PRECAUTIONS

- Initial therapy: Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting LIPIDIL therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (beta-blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy.
- Continued therapy: Periodic determination of serum lipids should be obtained during initial
 therapy in order to establish the lowest effective dose of LIPIDIL. Therapy should be withdrawn
 in patients who do not have an adequate response after two months of treatment with the
 maximum recommended dose of 300 mg/day.
- 3. Prescreetitis has been sepected in patients taking feneliheats, gamiliocati, and ciofficate. This occurrence may represent a failure of efficacy or a secondary phenomenon through biliary tract stone or sludge formation and obstruction of the common bile duct.
- 4. Hypersensitivity Reactions: Acute hypersensitivity reactions including severe skin rashes requiring patient hospitalization and treatment with steroids have occurred very rarely during treatment with LIPEDEL. Unicaria was seen in 1.25 vs 0%, and rash in 2.82 vs 1.23% of fenofibrate and placebo patients respectively in controlled trials.
- 5. Hematologic Changes: Mild to moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients following initiation of LIPIDIL therapy. However, these levels stabilize during long-turm administration. Extremely rare spontaneous reports of thrombocytopenia and aganuslocytosis have been received during post-marketing surveillance outside of the U.S. Periodic blood counts are recommended during the first 12 months of LIPIDIL administration.
- 6. Skeletal numerie: The use of fibrates alone, including LIPIDIL may occasionally be associated with myositis. Treatment with drugs of the fibrate class has been associated on rare occasions with rhabdomyolysis, usually in patients with impaired renal function. Myopathy should be considered in any patient with diffuse mysigias, muscle tenderness or weakness, and/or marked elevations of creatinine phosphokinase levels.

Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms, and fenofibrate therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed.

7. Drug interactions:

- (A) Oral Anticongulants: CAUTION SHOULD BE EXERCISED WHEN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH LIPIDIL. THE DOSAGE OF THE ANTICOAGULANTS SOCULD BE REDUCED TO MAINTAIN THE PROTHEROMEN TIME AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. PROQUENT PROTHEROMEN SUBMINISMATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEPORTELY DETERMINED THAT THE PROTHEROMEN LEVEL HAS STABILIZED.
- (B) HhdG-CoA seductors inhibitors: Rhabdenyolysis has occurred when lovanistic was administered in continued through with granifered, a compound of the fibrate class soluted to fenciliate. In most patients who have had an unsatisfactory lipid response to either deng alove, any possible bandle of annihined through with an HMG-CoA reductors inhibitor and LIPIDIL is not outweighted by the siels of severe myopathy, rhabdenyolysis, and acute renal failure. There is no assument that periodic mostlessing of creating kinase will prevent the occurrence of severe myopathy and hidney damage.
- (C) Resine: Since bile acid sequestrants may bind other drugs given concurrently, patients should take LIPIDEL at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.
- (D) Cyclespesia: Because cyclesporin can produce nephrotoxicity with decrease in creatine clearance and rises in serian creatinine, and because renal excretion is the primary elimination route of fibrate drugs including LIPIDIL, there is a risk that an interaction will lead to deterioration. The benefits and risks of using LIPIDIL with immunosuppressants and other potentially rephrotoxic agents should be carefully considered, and the lowest effective dose 'employed.
- 8. Careinogenesis, Mutagenesis, Impairment of Fertility: In a 24-month study in rats (10, 45, and 200 mg/kg; 0.3, 1, and 6 times the maximum recommended human dose on the basis of mg/meter³ of susface area), the incidence of liver carcinoma was significantly increased at 6 times the maximum recommended human dose in males and females. A statistically significant increase in pancreatic carcinomas occurred in males at 1 and 6 times the maximum.

Revised: November 12, 1998

*

÷

recommended human dose; there were also increases in pancreatic adenomas and benigh testicular interstitial cell tumors at 6 times the maximum recommended human dose in males. In a second 24-month study in a different strain of rats (doses of 10 and 60 mg/kg; 0.3 and 2 times the maximum recommended human dose based on mg/meter³ surface area), there were significant increases in the incidence of pancreatic acinar adenomas in both sexes and increases in interstitial cell tumors of the testes at 2 times the maximum recommended human dose.

A comparative carcinogenicity study was done in rats comparing three drugs: fenofibrate (10 and 70 mg/kg; 0.3 and 1.6 times the maximum recommended human dose), clofibrate (400 mg/kg; 1.6 times the human dose), and gemfibrozil (250 mg/kg; 1.7 times the human dose) (multiples based on mg/meter³ surface area). Pancreatic acinar adenomas were increased in males and females on fenedicate; hepatocellular carcinoma and pancreatic acinar adenomas were increased in males and hepatic neoplastic nodules in females treated with clofibrate; hepatic neoplastic nodules were increased in males and females treated with gemfibrozil while testicular intentitiel cell tumess were increased in males on all three drugs.

In a 21-month study in mise at doses of 10, 45, and 200 mg/kg (approximately 0.2, 0.7 and 3 times the maximum recommended human dose on the basis of mg/mster² surface area), there were statistically significant increases in liver carcinoma at 3 times the maximum recommended human dose in both make and females. In a second 18-month study at the same doses, there was a significant increase in liver carcinoma in male mice and liver adenoma in female mice at 3 times the maximum recommended human dose.

Fencilibrate has been demonstrated to be devoid of mutagenic potential in the following tests: Ames, mouse lymphoma, chromosomal aberration and unscheduled. DNA synthesis.

9. Pregnancy Category C: Fenofibrate has been shown to be embryocidal and teratogenic in rats when given in doses 7 to 10 times the maximum recommended human dose and embryocidal in rabbits when given at 9 times the maximum recommended human dose (on the basis of mg/meter² surface area). There are no adequate and well-controlled studies in pregnant women. Fenofibrate should be used during pregnancy only if the potential benefit justifies the potential visit to the fetus.

Administration of 9 times the maximum recommended human dose of fenofibrate to female rats before and throughout gestation caused 100% of dams to delay delivery and resulted in a 60% increase in post-implantation loss, a decrease in litter size, a decrease in birth weight, a 40% survival of pups at birth, a 4% survival of pups as neonates, and a 0% survival of pups to weaning, and an increase in spina bifids.

Administration of 10 times the maximum recommended human dose to female rats on days 6-15 of gestation caused an increase in gross, viscoral and skeletal findings in fetuses (domed head/hunched shoulders/rounded body/abnormal chest, kyphosis, stunted fetuses, elongated sternal ribs, malformed sternebrae, extra foramen in palatine, misshapen vertebrae, supernumerary ribs).

Administration of 7 times the maximum recommended human dose to female rats from day 15 of gestation through wearing caused a delay in delivery, a 40% decrease in live births, a 75% decrease in neonatal survival, and decreases in pup weight, at birth as well as on days 4 and 21 post-partum.

Administration of 9 and 18 times the maximum recommended human dose to female rabbits caused abortions in 10% of dams at 9 times and 25% of dams at 18 times the maximum recommended human dose and death of 7% of setuses at 18 times the maximum recommended human dose.

- 10. Number mothers: For eithers should not be used in musting mothers. Because of the potential for tumoriganicity seen in animal studies, a decision should be made whether to discontinue running or to discontinue the drug.
- 11. Use in Children: Safety and efficacy in children have not been established.

ADVERSE REACTIONS

CLINICAL: Adverse events reported by 1% or more of patients treated with LIPIDIL during the six month and the eight week double-blind, placebo-controlled trials in the U.S.¹⁹ are listed in the table below. Adverse events led to discontinuation of treatment in 6% of patients treated with LIPIDIL and in 2% treated with placebo. Skin rashes were the most frequent events, causing discontinuation of LIPIDIL treatment in 2% of patients in double-blind trials.

ODY SYSTEM	LIPIDIL	PLACEBO	
Advence Event	(N = 191)	(N = 183)	
NOOY AS A WHOLE			
Asthenia/Fetigue	5%	3%	
Aginania/ resigner	19%	15%	
Flu Syndrome	5%	2%	
Localized/Misc. Pain	8%	7%	
Headache	5%	4%	
CARDIOVASCULAR			
	1%	1%	
Azrhythmia			
DICESTIVE	5%	7%	
Dyupopain	1%	0%	
Eructation	3%	2%	
Flatulance	4%	2%	
Names/Vomiting		3%	
Abdominal Pain	3%	2%	
Constiguition	3%		
Dissilian	. 3%	· />	
MUSCULOSSILETAL		47	
Arthrolgin	3%	4%	
NERVOUS		4 00	
Decreased Libido	2%	1%	
Persethania ·	15	. 2%	
Incurred Appetite	1%	1%	
Dissipans	25	1%	
Issounda	., 15	15	
RESPERATORY			
Cough	1%	1%	
Rhiettis	4%	3%	
Simusitie	1%	1%	
SKIN & APPENDAGES			
Pruritus	3%	1%	
Rash	6%	2%	
SPECIAL SENSES			
Sauche	1%	1%	
Eye Manten	1%	0%	
Blagged Vision	1%	1%	
Conjunctivitis	15	2%	
Bye Instation	2%	1%	
UROGENITAL			
Polyuria	1%	1%	
Vaginitis	. 1%	. 1%	

Additional clinical adverse events reported by fewer than 1% of patients in the U.S. double-blind studies, those reported in other clinical trials, and spontaneously reported in post-marketing surveillance outside the U.S. are listed below, categorized by causality:

PROBABLY CAUSALLY RELATED: Digestive: hepatitis, cholelithiasis, cholecystitis, hepatomegaly; Muscultohaletal: myalgia, myasthenia, rhabdomyolysis; Skin and appendages: photosensitivity, eczema; Respiratory: allergic pulmonary alveolitis.

CAUSAL RELATIONSHIP NOT ESTABLISHED: Body as a whole: facial edema, weight decrease, fever, epistaxis; Cardiovascular: peripheral edema, angina, palpitations, tachycardia, migraine; Digastive: hemateusesis, pencuentitis; Respiratory: congestion; Nervous: dry mouth, vertigo, anxiety, sleep disorders, confesion; Stein and appendages: lupus-like syndrome, ichthyosis, telangioctasis, alopecia; Special senses: amblyopia, tirmitus; Urogenitai: decreased male fertility, renal lithlasis.

LABORATORY: In the two U.S. placebo controlled studies, serum transaminance determinations (SGPT and/or SGOT) were increased to over three times the upper normal limit in 8 to 10% of patients taking Lipidil at deess of 300 mg/day (See WARNINGS). Other changes that occurred more frequently during Lipidil treatment compared to placebo included increases in creatinine and blood urea, and decreases in homoglobin and usic acid.

Additional inhoratory findings that have been reported during fenofibrate treatment that are probably causally related include: anomia, leucopenia, ensinophilia, thrombocytopenia, and increased creatinine phospholimuse.

DOSAGE AND ADMENISTRATION

Patients should be placed on an appropriate triglyceride-lowering diet before receiving LIPIDIL, and should continue this diet during treatment with LIPIDIL.

LIPIDIL should be given with meals. The initial dose is usually 100 mg per day, depending on the physician's assessment of the patient's risk for pancrestitis (see INDICATIONS AND USAGE). Dosage should be individualized according to patient response, and should be increased sequentially if necessary following repeat serum triglyceride estimations at 4-to-8 week intervals. The maximum dose is 300 mg/day.

:

Treatment with LIPIDIL should be initiated at a dose of 100 mg/day in patients having impaired renal function, and increased only after evaluation of the effects on renal function and triglyceride levels at this dose. In the elderly, the initial dose should likewise be limited to 100 mg/day.

OVERDOSAGE

Because fenofibrate is highly bound to plasma proteins, hemodialysis should not be considered.

While there has been no reported case of overdosage, symptomatic supportive measures should be taken should it occur.

HOW SUPPLIED

LIPIDIL (funofibrate) is available as epoque white hard guiatin capsules. Each capsule contains 160 mg fenofibrate. Each capsule is putated with "LIFIDIL". LIFIDIL is available in bottles of 90 and hottles of 1000.

> NDC 9007-0709-41 NDC 0007-0709-03

Bottles of 90 Bottles of 1000

STORAGE

Store in a cool dry place. Protect from temperatures above 30°C (86°F). Avoid excessive light and humidity.

Distributed by

POURNIER RESEARCH INC. 689 Mamaroneck Avenue P.O.Box 340 MAMARONECK N.Y. 10543

CAUTION-Federal law probabits dispersing without prescription.

REFERENCES

- Goldberg AC, et al: Fanofibrate for the Treatment of Type IV and V Hyperlipoproteinemias: A Double-Blind, Placebo-Controlled Multicenter US Study. Clinical Therapeutics 11: 69-83, 1989.
- Nikkila EA: Familial Lipoprotein Lipase deficiency and related disorders of chylomicron metabolism. In Stanbury J.B. et al. (eds.): The Metabolic Basis of Inherited Disease, 5th edition, Mc Graw - Hill, 1963, Chap. 30, pp. 622-642.
- 3. Brown WV, et al: Effects of Fenefibrate on Plasma Lipids: Double-Blind, Multicenter Study in Patients with Type IIA or IIB Hyperlipidemia. Arteriosclerosis & 670-678, 1986.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 19-304/S005

FINAL PRINTED LABELING

(Nos. 4342,6415, 6447) —— NEW —

TRICOR ®

(fenofibrate capsules), micronized

R_x Only

DESCRIPTION

TRICOR (fenofibrate capsules), micronized, is a lipid regulating agent available as capsules for oral administration. Each capsule contains 67 mg, 134 mg or 200 mg of micronized fenofibrate. The chemical name for fenofibrate is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid. 1-methylethyl ester with the following structural formula:

The empirical formula is C₂₀H₂₁O₄C1 and the molecular weight is 360.83: fenofibrate is insoluble in water. The melting point is 79-82°C. Fenofibrate is a white solid which is stable under ordinary conditions.

Inactive Ingredients: Each capsule also contains crospovidone, iron oxide, lactose, magnesium stearate, pregelatinized starch, sodium jauryl sulfate, and titanium dioxide.

CLINICAL PHARMACOLOGY

A variety of clinical studies have demonstrated that elevated levels of total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apo B), an LDL membrane complex, are associated with human atherosclerosis. Similarly, decreased levels of high density lipoprotein cholesterol (HDL-C) and its transport complex, apolipoprotein A (apo Al and apo All) are associated with the development of atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C, and triglycerides, and inversely with the level of HDL-C. The independent effect of raising HDL-C or lowering triglycerides (TG) on the risk of cardiovascular morbidity and mortality has not been determined.

Fenofibric acid, the active metabolite of fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAl and apoAII.

The effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPAR α). Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein α -III (an inhibitor of lipoprotein lipase activity). The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for

cholesterol receptors and are catabolized rapidly. Activation of PPARa also induces an increase in the synthesis of apoproteins A-l, A-II and HDL-cholesterol.

Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid.

Pharmacokinetics/Metabolism

Clinical experience has been obtained with two different formulations of fenofibrate: a "micronized" and "non-micronized" formulation, which have been demonstrated to be bioequivalent. Comparisons of blood levels following oral administration of both formulations in healthy volunteers demonstrate that a single capsule containing 67 mg of the "micronized" formulation is bioequivalent to 100 mg of the "non-micronized" formulation. Three capsules containing 67 mg TRICOR are bioequivalent to a single 200 mg TRICOR capsule... Absorption

The absolute bioavailability of fenofibrate cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection. However, fenofibrate is well absorbed from the gastrointestinal tract. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate, and 25% was excreted in the feces. Peak plasma levels of -fenofibric acid occur within 6 to 8 hours after administration.

The absorption of fenofibrate is increased when administered with food. With micronized fenofibrate, the absorption is increased by approximately 35% under fed as compared to fasting conditions.

Distribution

In healthy volunteers, steady-state plasma levels of fenofibric acid were shown to be achieved within 5 days of dosing with single oral doses equivalent to 67 mg TRICOR and did not demonstrate accumulation across time following multiple dose administration. Serum protein binding was approximately 99% in normal and hyperlipidemic subjects. - -Metabolism

Following oral administration, fenofibrate is rapidly hydrolyzed by esterases to the active metabolite, fenofibric acid; no unchanged fenofibrate is detected in plasma.

Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. A small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite which is, in turn, conjugated with glucuronic acid and excreted in urine.

In vivo metabolism data indicate that neither fenofibrate nor fenofibric acid-undergo oxidative metabolism (e.g., cytochrome P450) to a significant extent.

Excretion

After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenosibric acid and fenosibric acid glucuronide. After administration of radiolabelled fenosibrate. approximately 60% of the dose appeared in the uring and 25% was excreted in the feces.

Fenofibric acid is eliminated with a half-life of 20 hours, allowing once daily administration in a clinical setting.

Special Populations

Geriatrics

In elderly volunteers 77 - 87 years of age, the oral clearance of fenoficiac acid following a single oral dose of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults. This indicates that a similar dosage regimen can be used in the elderly, without increasing accumulation of the drug or metabolites.

Pediatrics

Page 3 of 13 CR 20-01404 DN0530V4 April 11, 2000

TRICOR has not been investigated in adequate and well-controlled trials in pediatric patients.

Gender

No pharmacokinetic difference between males and females has been observed for fenofibrate. Race

The influence of race on the pharmacokinetics of fenofibrate has not been studied, however fenofibrate is not metabolized by enzymes known for exhibiting inter-ethnic variability. Therefore, inter-ethnic pharmacokinetic differences are very unlikely.

Renal insufficiency

In a study in patients with severe renal impairment (creatinine clearance < 50 mL/min), the rate of clearance of fenofibric acid was greatly reduced, and the compound accumulated during chronic dosage. However, in patients having moderate renal impairment (creatinine clearance of 50 to 90 mL/min), the oral clearance and the oral volume of distribution of fenofibric acid are increased compared to healthy adults (2.1 L/h and 95 L versus 1.1 L/h and 30 L, respectively). Therefore, the dosage of TRICOR should be minimized in patients who have severe renal impairment, while no modification of dosage is required in patients having moderate renal impairment.

Hepatic insufficiency

No pharmacokinetic studies have been conducted in patients having hepatic insufficiency. Drug-drug interactions

In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.

Potentiation of coumarin-type anticoagulants has been observed with prolongation of the prothrombin time/INR.

Bile acid sequestrants have been shown to bind other drugs given concurrently. Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption. (See WARNINGS and PRECAUTIONS).

Clinical Trials

Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb)

The effects of fenofibrate at a dose equivalent to 200 mg TRICOR per day were assessed from-four randomized, placebo-controlled, double-blind, parallel-group studies including patients with the following mean baseline lipid values: total-C 306.9 mg/dL; LDL-C 213.8 mg/dL; HDL-C 52.3 mg/dL: and triglycerides 191.0 mg/dL. TRICOR therapy lowered LDL-C, Total-C, and the LDL-C/HDL-C ratio. TRICOR therapy also lowered triglycerides and raised HDL-C (see Table 1).

Mean Percent Change in Lipid Parameters at End of Treatment

Treatment Group	ge in Lipid Paramet	LDL-C	HDL-C	
Pooled Cohort		-	חשביר	TG
Mean baseline lipid values (n=646) All FEN (n=361) Placebo (n=285)	306.9 mg/dL -18.7%* -0.4%	213.8 mg/dL -20.6%* -2.2%	52.3 mg/dL +11.0%* +0.7%	191.0 mg/di -28.9%*
Baseline LDL-C > 160 mg/dL and			10.776	+7.7%
TG < 150 mg/dL (Type IIa)	ļ .	-	İ	
Mean baseline lipid values (n=334) All FEN (n=193) Placebo (n=141)	307.7 mg/di_ -22.4%* +0.2%	227.7 mg/dL -31.4%* -2.2%	58.1 mg/dL +9.8%*	101.7 mg/dl -23.5%*
Baseline LDL-C > 160 mg/dL and		-2.276	+2.6%	+11.7%
$TG \ge 150 \text{ mg/dL } (Type IIb)$		1		
Mean baseline lipid values (n=242) All FEN (n=126) Placebo (n=116)	312.8 mg/dL -16.8%* -3.0%:	219.8 mg/dL -20.1%* -6.6%	46.7-mg/dL _ +14.6%* +2.3%	231.9 mg/dl -35.9%* +0.9%

^{*} Duration of study treatment was 3 to 6 months.

In a subset of the subjects, measurements of apo B were conducted. TRICOR treatment significantly reduced apo B from baseline to endpoint as compared with placebo (-25.1% vs. 2.4%, p<0.0001, n=213 and 143 respectively).

Hypertriglyceridemia (Fredrickson Type IV and V)

The effects of fenofibrate on serum triglycerides were studied in two randomized, double-blind, placebo-controlled clinical trials of 147 hypertriglyceridemic patients (Fredrickson Types IV and V). Patients were treated for eight weeks under protocols that differed only in that one entered patients with baseline triglyceride (TG) levels of 500 to 1500 mg/dL, and the other TG levels of 350 to 500 mg/dL. In patients with hypertriglyceridemia and normal cholesterolemia with or without hyperchylomicronemia (Type IV/V hyperlipidemia), treatment with fenofibrate at dosages equivalent to 200 mg TRICOR per day decreased primarily very low density lipoprotein (VLDL) triglycerides and VLDL cholesterol. Treatment of patients with Type IV hyperlipoproteinemia and elevated triglycerides often results in an increase of low density lipoprotein (LDL) cholesterol (see Table 2).

[•] p = <0.05 vs. Placebo

Effects of TRICOR in Patients With Fredrickson Type IV/V Hyperlipidemia

Study 1	Plac	ebo		a rreuricisoi		COR	e. apiecinia	
Baseline TG levels 350 to 499 mg/dL	Ñ	Baseline (Mean)	Endpoint (Mean)	% Change (Mean)	N	Baseline (Mean)	Endpoint (Mean)	% Change (Mean)
Triglycerides	28	449	450	-0.5	27	432	223	-46.2°
VLDL Triglycerides	19	367	350	2.7	19	350	178	-44.1*
Total Cholesterol	28	255	261	2.8	27	252	227	-9.1*
HDL Cholesteroi	28	35	36	4	27	. 34	40	19.6*
LDL Cholesterol	28	120	129	12	27	128	137	
VLDL Cholesterol	27	99	99	5.8	27	92	46	14.5
Study 2	Plac	ebo				COR		-44.7*
Baseline TG levels 500 to 1500 mg/dL	N	Baseline (Mean)	Endpoint (Mean)	% Change (Mean)	N	Baseline (Mean)	Endpoint (Mean)	% Change (Mean)
Triglycerides	44	710	750 _	7.2	48	726	308	-54.5*
VLDL Triglycerides	29	537	571	18.7	33	543	205	-50.6°
Total Cholesterol	44	272	271	0.4	48	261	222	12.22
HDL Cholesterol	44	27	28	5.0	48	30	223 36	-13.8* 22.9*
LDL Cholesterol	42	100	90	-4.2	45			
VLDL Cholesterol	42	137	142	. 11.0	45	103 126	131	- 45.0*
p<005 vs Placebo					73	120	54	-49 4*

The effect of TRICOR on cardiovascular morbidity and mortality has not been determined.

INDICATIONS AND USAGE

Treatment of Hypercholesterolemia

TRICOR is indicated as adjunctive therapy to diet for the reduction of LDL-C. Total-C. Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below).

Treatment of Hypertriglyceridemia

TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.

Markedly elevated levels of serum triglycerides (e.g. > 2.000 mg/dL) may increase the risk of developing pancreatitis. The effect of TRICOR therapy on reducing this risk has not been adequately studied.

Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types J. IV and V hyperlipoproteinemia.

The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as

hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia.

The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS).

Fredrickson Classification of Hyperlipoproteinemias

•		Lipid Elevation	
Туре	Lipoprotein Elevated	Major	Minor
l (rare)	chylomicrons	TG	1-C
lla	LDL		
llb	LDLVLDL	··· č	TG
III (rare)	IDL	C, TG	10
IV	VLDL	TG	1-C
V (rare)	chylomicrons, VLDL	TG	1-0

(=choiesterol.

TG=trigly cerides

LDI =low density lipoprotein

VLDI =very low density hipoprotein

IDI =imermediate density lipoprotein

The NCEP Treatment Guideline

_		The received of the state of th		•
	Definite Athlerosclerotic Disease*	Two or More Other Risk Factors ^b	LDL-Cholesteral mg/dL (mmol/L)	
_		-	Initiation Level	Goal
	No	No	≥ 190 (≥ 4.9)-	< 160 (< 4.1)
-	- No	Yes	≥ 160 (≥ 4.1)	< 130 (< 3.4)
121.6	Yes	Yes or No	≥ 130° (≥ 3.4)	< 100 (< 2.6)

oronary heart disease or peripheral vascular disease tincluding symptomatic carotid artery disease).

c in CHD patients with EDL-C levels 100 to 129 mg/dL, the physician should exercise clinical judgment in deciding whether to initiate drug treatment

CONTRAINDICATIONS

TRICOR is contraindicated in patients who exhibit hypersensitivity to fenofibrate.

TRICOR is contraindicated in patients with hepatic or severe renal dysfunction, including primary biliary cirrhosis, and patients with unexplained persistent liver function abnormality.

TRICOR is contraindicated in patients with preexisting gallbladder disease (see WARNINGS:

WARNINGS

Liver Function: Fenofibrate at doses equivalent to 134 mg to 200 mg TRICOR per day has been associated with increases in serum transaminases [AST (SGOT) or ALT (SGPT)]. In a pooled analysis of 10 placebo-controlled trials, increases to > 3 times the upper limit of normal occurred in 5.3% of patients taking fenofibrate versus 1.1% of patients treated with placebo.

When transaminase determinations were followed either after discontinuation of treatment or during continued treatment, a return to normal limits was usually observed. The incidence of increases in transaminases related to fenofibrate therapy appear to be dose-related. In an 8-week dose-ranging study, the incidence of ALT or AST elevations to at least three times the upper

⁽h) Other risk factors for commany heart disease (CHD) include age (males: 245 years; females: 255 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (<0.91 mmol 1.), and disheres mellitus Subtract 1 risk factor if HDL-C is >60 mg/dL (>1.6 mmol/L)

limit of normal was 13% in patients receiving dosages equivalent to 134 mg to 200 mg TRICOR per day and was 0% in those receiving dosages equivalent to 34 mg or 67 mg TRICOR per day. or placebo. Hepatocellular, chronic active and cholestatic hepatitis associated with fenofibrate therapy have been reported after exposures of weeks to several years. In extremely rare cases, cirrhosis has been reported in association with chronic active hepatitis.

Regular periodic monitoring of liver function, including serum ALT (SGPT) should be performed for the duration of therapy with TRICOR, and therapy discontinued if enzyme levels persist above three times the normal limit.

Cholelithiasis: Fenofibrate, like clofibrate and gemfibrozil, may increase cholesterol excretion into the bile, leading to cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated. TRICOR therapy should be discontinued if gallstones are found.

Concomitant Oral Anticoagulants: Caution should be exercised when anticoagulants are given in conjunction with TRICOR because of the potentiation of coumarin-type anticoagulants in prolonging the prothrombin time/INR. The dosage of the anticoagulant should be reduced to maintain the prothrombin time/INR at the desired level to prevent bleeding complications. Frequent prothrombin time/INR determinations are advisable until it has been definitely determined that the prothrombin time/INR has stabilized.

Concomitant HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.

In a single-dose drug interaction study in 23 healthy adults the concomitant administration of TRICOR and pravastatin resulted in no clinically important difference in the pharmacokinetics of fenofibric acid, pravastatin or its active metabolite 3a-hydroxy iso-pravastatin when compared to either drug given alone.

The combined use of fibric acid derivatives and HMG-CoA reductase inhibitors has been associated, in the absence of a marked pharmacokinetic interaction, in numerous case reports, with rhabdomyolysis, markedly elevated creatine kinase (CK) levels and myoglobinuria, leading in a high proportion of cases to acute renal failure.

The use of fibrates alone, including TRICOR, may occasionally be associated with myositis, myopathy, or rhabdomyolysis. Patients receiving TRICOR and complaining of muscle pain, tenderness, or weakness should have prompt medical evaluation for myopathy, including serum creatine kinase level determination. If myopathy/myositis is suspected or diagnosed. TRICOR therapy should be stopped.

Mortality: The effect of TRICOR on coronary heart disease morbidity and mortality and noncardiovascular mortality has not been established.

Other Considerations: In the Coronary Drug Project, a large study of post myocardial infarction of patients treated for 5 years with clofibrate, there was no difference in mortality seen between the clofibrate group and the placebo group. There was however, a difference in the rate of cholelithiasis and cholecystitis requiring surgery between the two groups (3.0% vs. 1.8%).

Because of chemical, pharmacological, and clinical similarities between TRICOR (fenofibrate capsules), micronized. Atromid-S (clofibrate), and Lopid (gemfibrozil), the adverse findings in 4 large randomized, placebo-controlled clinical studies with these other fibrate drugs may also apply to TRICOR.

In a study conducted by the World Health Organization (WHO), 5000 subjects without known coronary arrery disease were treated with placebo or clofibraty for 5 years and followed for an additional one year. There was a statistically significant, higher age-adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p=<0.01). Excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy,

post-cholecystectomy complications, and pancreatitis. This appeared to confirm the higher risk of gallbladder disease seen in clofibrate-treated patients studied in the Coronary Drug Project.

The Helsinki Heart Study was a large (n=4081) study of middle-aged men without a history of coronary artery disease. Subjects received either placebo or gemfibrozil for 5 years, with a 3.5 year open extension afterward. Total mortality was numerically higher in the gemfibrozil randomization group but did not achieve statistical significance (p=0.19, 95% confidence interval for relative risk G:P=.91-1.64). Although cancer deaths trended higher in the gemfibrozil group (p=0.11), cancers (excluding basal cell carcinoma) were diagnosed with equal frequency in both study groups. Due to the limited size of the study, the relative risk of death from any cause was not shown to be different than that seen in the 9 year follow-up data from World Health Organization study (RR=1.29). Similarly, the numerical excess of gallbladder surgeries in the gemfibrozil group did not differ statistically from that observed in the WHO study.

A secondary prevention component of the Helsinki Heart Study enrolled middle-aged men excluded from the primary prevention study because of known or suspected coronary heart disease. Subjects received gemfibrozil or placebo for 5 years. Although cardiac deaths trended higher in the gemfibrozil group, this was not statistically significant (hazard ratio 2.2, 95% confidence interval: 0.94-5.05). The rate of gallbladder surgery was not statistically significant between study groups, but did trend higher in the gemfibrozil group, (1.9% vs. 0.3%, p=0.07). There was a statistically significant difference in the number of appendectomies in the gemfibrozil group (6/311 vs. 0/317, p=0.029).

PRECAUTIONS.

Initial therapy: Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting TRICOR therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (beta-blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy.

Continued therapy: Periodic determination of serum lipids should be obtained during initial therapy in order to establish the lowest effective dose of TRICOR. Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 200 mg per day.

Pancreatitis: Pancreatitis has been reported in patients taking fenofibrate, gemfibrozil, and clofibrate. This occurrence may represent a failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.

Hypersensitivity Reactions: Acute hypersensitivity reactions including severe skin rashes requiring patient hospitalization and treatment with steroids have occurred very rarely during treatment with fenofibrate, including rare spontaneous reports of Stevens-Johnson Syndrome, and toxic epidermal necrolysis. Urticaria was seen in 1.1 vs 0%, and rash in 1.4 vs 0.8% of fenofibrate and placebo patients respectively in controlled trials.

Hematologic Changes: Mild to moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients following initiation of fenofibrate therapy. However, these levels stabilize during long-term administration. Extremely rare spontaneous reports of thrombocytopenia and agranulocytosis have been received during post-marketing surveillance outside of the U.S. Periodic blood counts are recommended during the first 12 months of TRICOR administration:

Skeletal muscle: The use of fibrates alone, including TRICOR, may occasionally be associated with myopathy. Treatment with drugs of the fibrate class has been associated on rare occasions with rhabdomyolysis, usually in patients with impaired renal function. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevations of creatine phosphokinase levels.

Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms, and fenofibrate therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed.

Drug Interactions

Oral Anticoagulants: CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED.

HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS).

Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.

Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration. The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed.

Carcinogenesis, Mutagenesis, Impairment of Fertility: In a 24-month study in rats (10, 45, and 200 mg/kg: 0.3. 1, and 6 times the maximum recommended human dose on the basis of mg/meter² of surface area), the incidence of liver carcinoma was significantly increased at 6 times the maximum recommended human dose in males and females. A statistically significant increase in pancreatic carcinomas occurred in males at 1 and 6 times the maximum recommended human dose; there were also increases in pancreatic adenomas and benign testicular interstitial cell tumors at 6 times the maximum recommended human dose in males. In a second 24-month study in a different strain of rats (doses of 10 and 60 mg/kg; 0.3 and 2 times the maximum recommended human dose based on mg/meter² surface area), there were significant increases in the incidence of pancreatic acinar adenomas in both sexes and increases in interstitial cell tumors of the testes at 2 times the maximum recommended human dose.

A comparative carcinogenicity study was done in rats comparing three drugs: fenofibrate (10 and 70 mg/kg; 0.3 and 1.6 times the maximum recommended human dose), clofibrate (400 mg/kg; 1.6 times the human dose), and gemfibrozil (250 mg/kg; 1.7 times the human dose) 'multiples based on mg/meter' surface area). Pancreatic acinar adenomas were increased in males and females on fenofibrate; hepatocellular carcinoma and pancreatic acinar adenomas were increased in males and hepatic neoplastic nodules in females treated with clofibrate; hepatic neoplastic nodules were increased in males and females treated with gemfibrozil while testicular interstitial cell tumors were increased in males on all three drugs.

In a 21-month study in mice at doses of 10, 45, and 200 mg/kg (approximately 0.2, 0.7 and 3 times the maximum recommended human dose on the basis of mg/meter² surface area). there were statistically significant increases in liver carcinoma at 3 times the maximum recommended human dose in both males and females. In a second 18-month study at the same doses, there was a significant increase in liver carcinoma in male mice and liver adenoma in female mice at 3 times the maximum recommended human dose.

Electron microscopy studies have demonstrated peroxisomal proliferation following fenofibrate administration to the rat. An adequate study to test for peroxisome proliferation in humans has not been done, but changes in peroxisome morphology and numbers have been observed in humans after treatment with other members of the fibrate class when liver biopsies were compared before and after treatment in the same individual.

Fenofibrate has been demonstrated to be devoid of mutagenic potential in the following tests: Ames, mouse lymphoma, chromosomal aberration and unscheduled DNA synthesis.

Pregnancy Category C: Fenofibrate has been shown to be embryocidal and teratogenic in rats when given in doses 7 to 10 times the maximum recommended human dose and embryocidal in rabbits when given at 9 times the maximum recommended human dose (on the basis of mg/meter² surface area). There are no adequate and well-controlled studies in pregnant women. Fenofibrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Administration of 9 times the maximum recommended human dose of fenofibrate to female rats before and throughout gestation caused 100% of dams to delay delivery and resulted in a 60% increase in post-implantation loss, a decrease in litter size, a decrease in birth weight, a 40% survival of pups at birth, a 4% survival of pups as neonates, and a 0% survival of pups to weaning, and an increase in spina bifida.

Administration of 10 times the maximum recommended human dose to female rats on days 6-15 of gestation caused an increase in gross, visceral and skeletal findings in fetuses (domed head/hunched shoulders/rounded body/abnormal chest, kyphosis, stunted fetuses, elongated sternal ribs, malformed sternebrae, extra foramen in palatine, misshapen vertebrae, supernumerary ribs).

Administration of 7 times the maximum recommended human dose to female rats from day 15 of gestation through weaning caused a delay in delivery, a 40% decrease in live births, a 75% decrease in neonatal survival, and decreases in pup weight, at birth as well as on days 4 and 21 post-partum.

Administration of 9 and 18 times the maximum recommended human dose to female rabbits caused abortions in 10% of dams at 9 times and 25% of dams at 18 times the maximum recommended human dose and death of 7% of fetuses at 18 times the maximum recommended human dose.

Nursing mothers: Fenofibrate should not be used in nursing mothers. Because of the potential for tumorigenicity seen in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug.

Pediatric Use: Safety and efficacy in pediatric patients have not been established.

Geriatric Use: Fenofibric acid is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection.

ADVERSE REACTIONS _

CLINICAL: Adverse events reported by 2% or more of patients treated with fenofibrate during the double-blind, placebo-controlled trials, regardless of causality, are listed in the table below. Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.

BODY SYSTEM Adverse Event	Fenofibrate* (N=439)	Placebo
BODY AS A WHOLE	(1. 10)	(N=365)
Abdominal Pain Back Pain Headache Asthenia	4.6% 3.4% 3.2% 2.1%	4.4% - 2.3% 2.7%
-Flu Syndrome DIGESTIVE	- 2.1%-	3.0% - 2.7%
Liver Function Tests Abnormal Diarrhea Nausea Constipation METABOLIC AND NUTRITIONAL DISOR	7.5%** 2.3% 2.3% 2.1% DERS	1.4% 1.1% 1.9% 1.4%
SGPT Increased - Creatine Phosphokinase Increased SGOT Increased RESPIRATORY	3.0% 3.0% 3.4% **	· 1.6% 1.4% 0.5%
Respiratory Disorder Rhinitis Dosage equivalent to 200 mg TRICOR	6.2% - 2.3%	5.5% 1.1%

Additional adverse events reported by three or more patients in placebo-controlled trials or reported in other controlled or open trials, regardless of causality are listed below.

BODY AS A WHOLE: Chest pain, pain (unspecified), infection, malaise, allergic reaction, cyst, hernia, fever, photosensitivity reaction, and accidental injury.

CARDIOVASCULAR SYSTEM: Angina pectoris, hypertension, vasodilatation, coronary artery disorder, electrocardiogram abnormal, ventricular extrasystoles, myocardial infarct, peripheral vascular disorder, migraine, varicose vein, cardiovascular disorder, hypotension, palpitation, vascular disorder, arrhythmia, phlebitis, tachycardia, extrasystoles, and atrial fibrillation.

DIGESTIVE SYSTEM: Dyspepsia, flatulence, nausea, increased appetite, gastroenteritis, cholelithiasis, rectal disorder, esophagitis, gastritis, colitis, tooth disorder, vomiting, anorexia, gastrointestinal disorder, duodenal ulcer, nausea and vomiting, peptic ulcer, rectal hemorrhage, liver fatty deposit, cholecystitis, eructation, gamma glutarnyl transpeptidase, nausea, vomiting, and diarrhea.

ENDOCRINE SYSTEM: Diabetes mellitus

HEMIC AND LYMPHATIC SYSTEM: Anemia. leukopenia, ecchymosis, eosinophilia, lymphadenopathy, and thrombocytopenia.

METABOLIC AND NUTRITIONAL DISORDERS: Creatinine increased, weight gain, hypoglycemia, gout, weight loss, edema, hyperuricemia, and peripheral edema. MUSCULOSKELETAL SYSTEM: Myositis, myalgia, arthralgia, arthritis, tenosynovitis, joint disorder, arthrosis, leg cramps, bursitis, and myasthenia.

NERVOUS SYSTEM: Dizziness, insomnia, depression, vertigo, libido decreased, anxiety, parasthesia, dry mouth, hypertonia, nervousness, neuralgia, and somnolence.

RESPIRATORY SYSTEM: Pharyngitis, bronchitis, cough increased, dyspnea, asthma, pneumonia, laryngitis, and sinusitis.

SKIN AND APPENDAGES: Rash, pruritis, eczema, herpes zoster, urticaria, acne. sweating, fungal dermatitis, skin disorder, alopecia, contact dermatitis, herpes simplex, maculopapular rash, nail disorder, and skin ulcer.

SPECIAL SENSES: Conjunctivitis, eye disorder, amblyopia, ear pain, otitis media, abnormal vision, cataract specified, and refraction disorder.

UROGENITAL SYSTEM: Urinary frequency, prostatic disorder, dysuria, kidney function abnormal, urolithiasis, gynocomastia, unintended pregnancy, vaginal moniliasis, and cystitis.

OVERDOSAGE

There is no specific treatment for overdose with TRICOR. General supportive care of the patient is indicated, including monitoring of vital signs and observation of clinical status, should an overdose occur. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage: usual precautions should be observed to maintain the airway. Because fenofibrate is highly bound to plasma proteins, hemodialysis should not be considered.

DOSAGE AND ADMINISTRATION

Patients should be placed on an appropriate lipid-lowering diet before receiving TRICOR, and should continue this diet during treatment with TRICOR. TRICOR should be given with meals, thereby optimizing the bioavailability of the medication.

For the treatment of adult patients with primary hypercholesterolemia or mixed hyperlipidemia, the initial dose of TRICOR is 200 mg per day.

For adult patients with hypertriglyceridemia, the initial dose is 67 to 200 mg per day. Dosage _ should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 200 mg per day.

Treatment with TRICOR should be initiated at a dose of 67 mg/day in patients having impaired renal function, and increased only after evaluation of the effects on renal function and lipid levels at this dose. In the elderly, the initial dose should likewise be limited to 67 mg/day.

Lipid levels should be monitored periodically and consideration should be given to reducing the dosage of TRICOR if lipid levels fall significantly below the targeted range.

HOW SUPPLIED

TRICOR® (fenofibrate capsules), micronized, is available as hard gelatin capsules in three strengths:

67 mg yellow capsules, imprinted with \blacksquare on cap and Abbo-Code identification letters FR on body, available in bottles of 90 (NDC 0074-4342-90) and Abbo-Pac packages of 100 (NDC 0074-4342-11).

134 mg white capsules, imprinted with \boxtimes on cap and Abbo-Code identification letters AR on body, available in bottles of 90 (NDC 0074-6447-90) and Abbo-Pac packages of 100 (NDC 0074-6447-11).

200 mg orange capsules, imprinted with 20 on cap and Abbo-Code identification letters SR on body, available in bottles of 90 (NDC 0074-6415-90) and Abbo-Pac packages of 100

(NDC 0074-6415-11).

Storage

Store at controlled room temperature, 15-30°C (59-86°F). Keep out of the reach of children. Protect from moisture.

Manufactured for Abbott Laboratories, North Chicago, IL 60064, U.S.A. by Laboratoires Fournier, S.A., 21300 Chenôve, France

Made in France

REFERENCES

1. GOLDBERG AC, et al. Fenofibrate for the Treatment of Type IV and V Hyperlipoproteinemias: A Double-Blind, Placebo-Controlled Multicenter US Study. Clinical Therapeutics, 11, pp. 69-83, 1989.

2. NIKKILA EA. Familial Lipoprotein Lipase Deficiency and Related Disorders of Chylomicron Metabolism. In Stanbury J.B., et al. (eds.): The Metabolic Basis of Inherited Disease, 5th edition. McGraw-Hill, 1983, Chap. 30, pp. 622-642.


3. BROWN WV, et al. Effects of Fenofibrate on Plasma Lipids: Double-Blind, Multicenter Study In Patients with Type IIA or IIB Hyperlipidemia. Arteriosclerosis. 6, pp. 670-678, 1986.

Revised: March, 2000

ABBOTT



PRINTED IN U.S.A.



HILW

THERAPEUM EQUIVALENCE EVALUATIONS

NOILIGE DE 2017

THE PRODUCTSIN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

EDOD AND DRUG ADMINISTRATION

CENTERFOR DRUGIEVADUATION AND RESEARCH

OFFICE OF INFORMATION TECHNOLOGY

DIVISION OF DATA MANAGEMENTIAND SERVICES

PRESCRIPTION DRUG PRODUCT LIST

+	TRICOR ABBOTT	TABLET: ORAL	+		:	TRICOR (MICRONIZED)	CARCITLE: ORAL		SEE ENALAPRIL MALEATE;	*MII TI DI .E*	+			ASTRAZENECA	XTENDED	FELODIPINE		+	WALLACE LABS	TABLET; ORAL	SUSPENSION; ORAL FELBATOL + WALLACE LABS	FELBAMATE
160MG	54MG			200MG	134MG	67MG			FELODIPINE		TONG	מאס כיי	SMG	2.5MG	RELEASE; ORAL			600MG	400MG		600MG/5ML	
N21203 003 SEP 04, 2001	N21203 001		JUN 30, 1999		**							JUL 25, 1991 N19834 002	4	N19834 004				v	JUL 29, 1993		N20189 003 JUL 29, 1993	
AB + DISTA	NALPON THE STATE OF THE STATE O	TATE ON LARS	AB PUREPAC PHARM	AB PAR PHARM	AB MYLAN	AB MUTUAL PHARM	AB LEDERLE	AB IVAX PHARMS	AB GENEVA PHARMS	PENOPROPEN CALCIUM DANBURY PHARMA		AB DISTA	AB + DISTA	NALFON	AB	AB PAR PHARM	AB .	AB GENEVA PHARMS	CAPSULE; ORAL	FENOPROFEN CALCIUM	INJECTABLE; INJECTION CORLOPAM + ABBOTT	FENOLDOPAM MESYLATE
BO 600MG BASE		EO 600MG BASE	EQ 600MG BASE	EQ 600MG BASE	EQ 600MG BASE	EQ 600MG BASE	EQ 600MG BASE	EQ 600MG BASE	BQ 600MG BASE	EQ 600MG BASE		EQ 200MG BASE	EQ 300MG HASE		EQ 300MG BASE	BQ 200MG BASE	BQ 300MG BASE	BQ 200MG BASE			EQ 10MG BASE/ML	
MT//TO COT	AUG 17, 1988	N72407 001	N72274 001 MAY 02, 1988	AUG 17, 1988	AUG 17, 1988	N72902 001 DEC 21, 1990	N72326 001 AUG 17, 1988	N72557 001 AUG 29, 1988	N72396 001 OCT 17, 1988	N72602 001 OCT 11, 1988		N17604 003		N17604 002	N72438 001 AUG 22, 1988	N72437 001 AUG 22, 1988	N72395 001 OCT 17, 1988	N72394 001 OCT 17, 1988			N19922 001 SEP 23, 1997	

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

020747 001 020747 002 020747 003 020747 003 020747 004 020747 005 020747 006 020195 002 020195 002 020195 003 020195 003	019304 002 019304 003 019304 004	021203 001	019834 004	019834 002	019834 001	020189 003	020189 002	020189 001	020902 001	020801 001	APPL/PROD NUMBER
OI FENTANYL CITRATE; ACTIQ OO2 FENTANYL CITRATE; ACTIQ OO3 FENTANYL CITRATE; ACTIQ OO3 FENTANYL CITRATE; ACTIQ OO4 FENTANYL CITRATE; ACTIQ OO5 FENTANYL CITRATE; ACTIQ OO6 FENTANYL CITRATE; ACTIQ OO7 FENTANYL CITRATE; FENTANYL OO7 FENTANYL; DURAGESIC FENTANYL; DURAGESIC FENTANYL; DURAGESIC	FENOFIBRATE; TRICOR (MICRONIZED) FENOFIBRATE; TRICOR (MICRONIZED) FENOFIBRATE; TRICOR (MICRONIZED) FENOFIBRATE; TRICOR (MICRONIZED)	FENOFIBRATE; TRICOR FENOFIBRATE; TRICOR	FELODIPINE; PLENDIL	FELODIPINE; PLENDIL	FELODIPINE; PLENDIL	Felbanate; Felbatol	FELBAMATE; FELBATOL	FELBAMATE; FELBATOL	FAMOTIDINE; PEPCID AC	FAMOTIDINE;PEPCID AC	INGREDIENT NAME; TRADE NAME
4671953 4671953 4671953 4671953 4671953 4671953 4671953 588580 4588580	4895726 4895726 4895726	6277405 6074670 4895726 6277405	4803081+PE 4895726	4803081*PE	4803081*PE	4978680 5082861	5082861 5082861	4820524*PED . 4978680 5082861	5854267*PED 5854267*PED 5854267*PED 5667794 5667794*PED 4820524	-5667794 5854267 5075114 5075114*PEI 5667794*PEI	PATENT NUMBER
MAY 01, 2000 MAY 0	JAN 19, 200 JAN 19, 200 JAN 19, 200	JAN 09, 20 JAN 09, 20 JAN 19, 20 JAN 09, 20	JAN 19, 20	OCT 03, 20	OCT 03, 20	SEP 26, 20	SEP 26, 20	AUG 20, 200 SEP 26, 200 SEP 26, 200	D JUN 29, 2016 DEC 29, 2015 D JUN 29, 2015 D MAY 02, 2015 D NOV 02, 2015 FEB 20, 2007	MAY 02, 201 DEC 29, 201 DEC 24, 200 JUN 24, 200 NOV 02, 201	PATENT EXPIRES
20000000000000000000000000000000000000	; ;	, , , , , , , , , , , , , , , , , , , 	• •	77		U-8		100 100 100 100 100 100 100 100 100 100	0-368 0-368 0-368 0-368	U-267	USE
	I-298 I-298 I-298 NCE	I-298	I-298						PED		CODE
	APR 24 APR 24 APR 24 SEP 23	APR 24	APR 24						MAY 09,		EXCLUS EXPIRES
	, 2003 , 2003 , 2003	, 2003	, 2003						2002		

• •

TRICOR®

(fenofibrate tablets)

R_x Only

DESCRIPTION

TRICOR (fenofibrate tablets), is a lipid regulating agent available as tablets for oral administration. Each tablet contains 54 mg or 160 mg of fenofibrate. The chemical name for fenofibrate is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester with the following structural formula:

The empirical formula is $C_{20}H_{21}O_4Cl$ and the molecular weight is 360.83; fenofibrate is insoluble in water. The melting point is 79-82°C. Fenofibrate is a white solid which is stable under ordinary conditions.

Inactive Ingredients: Each tablet contains colloidal silicon dioxide, crospovidone, lactose monohydrate, lecithin, microcrystalline cellulose, polyvinyl alcohol, povidone, sodium lauryl sulfate, sodium stearyl fumarate, talc, titanium dioxide, and xanthan gum.

In addition, individual tablets contain:

54 mg tablets: D&C Yellow No. 10, FD&C Yellow No. 6, FD&C Blue No. 2.

CLINICAL PHARMACOLOGY

A variety of clinical studies have demonstrated that elevated levels of total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apo B), an LDL membrane complex, are associated with human atherosclerosis. Similarly, decreased levels of high density lipoprotein cholesterol (HDL-C) and its transport complex, apolipoprotein A (apo Al and apo AII) are associated with the development of atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C, LDL-C, and triglycerides, and inversely with the level of HDL-C. The independent effect of raising HDL-C or lowering triglycerides (TG) on the risk of cardiovascular morbidity and mortality has not been determined.

Fenofibric acid, the active metabolite of fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.

The effects of fenofibric acid seen in clinical practice have been explained *in vivo* in transgenic mice and *in vitro* in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPAR α). Through this mechanism, fenofibrate increases lipolysis and elimination of

triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity).

The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. Activation of PPAR α also induces an increase in the synthesis of apoproteins A-I, A-II and HDL-cholesterol.

Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid.

Pharmacokinetics/Metabolism

Plasma concentrations of fenofibric acid after administration of 54 mg and 160 mg tablets are equivalent under fed conditions to 67 and 200 mg capsules, respectively.

Absorption

The absolute bioavailability of fenofibrate cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection. However, fenofibrate is well absorbed from the gastrointestinal tract. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate, and 25% was excreted in the feces. Peak plasma levels of fenofibric acid occur within 6 to 8 hours after administration.

The absorption of fenofibrate is increased when administered with food. With fenofibrate tablets, the extent of absorption is increased by approximately 35% under fed as compared to fasting conditions.

Distribution

In healthy volunteers, steady-state plasma levels of fenofibric acid were shown to be achieved within 5 days of dosing and did not demonstrate accumulation across time following multiple dose administration. Serum protein binding was approximately 99% in normal and hyperlipidemic subjects. *Metabolism*

Following oral administration, fenofibrate is rapidly hydrolyzed by esterases to the active metabolite, fenofibric acid; no unchanged fenofibrate is detected in plasma.

Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. A small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite which is, in turn, conjugated with glucuronic acid and excreted in urine.

In vivo metabolism data indicate that neither fenofibrate nor fenofibric acid undergo oxidative metabolism (e.g., cytochrome P450) to a significant extent.

Excretion

After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide. After administration of radiolabelled fenofibrate, approximately 60% of the dose appeared in the urine and 25% was excreted in the feces.

Fenofibric acid is eliminated with a half-life of 20 hours, allowing once daily administration in a clinical setting.

Special Populations

Geriatrics

In elderly volunteers 77. - 87 years of age, the oral clearance of fenofibric acid following a single oral dose of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults. This indicates that a similar dosage regimen can be used in the elderly, without increasing accumulation of the drug or

metabolites.

Pediatrics

TRICOR has not been investigated in adequate and well-controlled trials in pediatric patients.

Gender

No pharmacokinetic difference between males and females has been observed for fenofibrate.

Race

The influence of race on the pharmacokinetics of fenofibrate has not been studied, however fenofibrate is not metabolized by enzymes known for exhibiting inter-ethnic variability. Therefore, inter-ethnic pharmacokinetic differences are very unlikely.

Renal insufficiency

In a study in patients with severe renal impairment (creatinine clearance < 50 mL/min), the rate of clearance of fenofibric acid was greatly reduced, and the compound accumulated during chronic dosage. However, in patients having moderate renal impairment (creatinine clearance of 50 to 90 mL/min), the oral clearance and the oral volume of distribution of fenofibric acid are increased compared to healthy adults (2.1 L/h and 95 L versus 1.1 L/h and 30 L, respectively). Therefore, the dosage of TRICOR should be minimized in patients who have severe renal impairment, while no modification of dosage is required in patients having moderate renal impairment.

Hepatic insufficiency

No pharmacokinetic studies have been conducted in patients having hepatic insufficiency.

Drug-drug interactions

In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.

Potentiation of coumarin-type anticoagulants has been observed with prolongation of the prothrombin time/INR.

Bile acid sequestrants have been shown to bind other drugs given concurrently. Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption. (See WARNINGS and PRECAUTIONS).

Clinical Trials

Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb)

The effects of fenofibrate at a dose equivalent to 160 mg TRICOR per day were assessed from four randomized, placebo-controlled, double-blind, parallel-group studies including patients with the following mean baseline lipid values: total-C 306.9 mg/dL; LDL-C 213.8 mg/dL; HDL-C 52.3 mg/dL; and triglycerides 191.0 mg/dL. TRICOR therapy lowered LDL-C, Total-C, and the LDL-C/HDL-C ratio. TRICOR therapy also lowered triglycerides and raised HDL-C (see Table 1).

Table 1
Mean Percent Change in Lipid Parameters at End of Treatment[†]

Treatment Group	Total-C	LDL-C	HDL-C	TG
Pooled Cohort				
Mean baseline lipid values (n=646)	306.9 mg/dL	213.8	52.3 mg/dL	191.0
All FEN (n=361)	-18.7%*	mg/dL	+11.0%*	mg/dL
Placebo (n=285)	-0.4%	-20.6%*	+0.7%	-28.9%*
		-2.2%		+7.7%
Baseline LDL-C > 160 mg/dL and				
TG < 150 mg/dL (Type IIa)				
Mean baseline lipid values (n=334)	307.7 mg/dL	227.7	58.1 mg/dL	101.7
All FEN (n=193)	-22.4%*	mg/dL	+9.8%*	mg/dL
Placebo (n=141)	+0.2%	-31.4%*	+2.6%	-23.5%*
		-2.2%		+11.7%
Baseline LDL-C > 160 mg/dL and				
TG ≥ 150 mg/dL (Type IIb)				
Mean baseline lipid values (n=242)	312.8 mg/dL	219.8	46.7 mg/dL	231.9
All FEN (n=126)	-16.8%*	mg/dL	+14.6%*	mg/dL
Placebo (n=116)	-3.0%	-20.1%*	+2.3%	-35.9%*
		-6.6%		+0.9%

[†] Duration of study treatment was 3 to 6 months.

In a subset of the subjects, measurements of apo B were conducted. TRICOR treatment significantly reduced apo B from baseline to endpoint as compared with placebo (-25.1% vs. 2.4%, p<0.0001, n=213 and 143 respectively).

Hypertriglyceridemia (Fredrickson Type IV and V)

The effects of fenofibrate on serum triglycerides were studied in two randomized, double-blind, placebo-controlled clinical trials of 147 hypertriglyceridemic patients (Fredrickson Types IV and V). Patients were treated for eight weeks under protocols that differed only in that one entered patients with baseline triglyceride (TG) levels of 500 to 1500 mg/dL, and the other TG levels of 350 to 500 mg/dL. In patients with hypertriglyceridemia and normal cholesterolemia with or without hyperchylomicronemia (Type IV/V hyperlipidemia), treatment with fenofibrate at dosages equivalent to 160 mg TRICOR per day decreased primarily very low density lipoprotein (VLDL) triglycerides and VLDL cholesterol. Treatment of patients with Type IV hyperlipoproteinemia and elevated triglycerides often results in an increase of low density lipoprotein (LDL) cholesterol (see Table 2).

^{*} p = <0.05 vs. Placebo

Table 2
Effects of TRICOR in Patients With Fredrickson Type IV/V Hyperlipidemia

Baselin e (Mean) 449 367	Endpoin t (Mean)	% Change (Mean)	N	Baselin e	Endpoin t (Mean)	% Change
(Mean) 449	450	(Mean)			t (Mean)	Change
449			ł	/B# \		
		0.5		(Mean)		(Mean)
367		-0.5	27	432	223	-46.2*
	350	2.7	19	350	178	-44.1*
255	261	2.8	27	252	227	- 9.1*
35	36	. 4	27	34	40	19.6*
120	129	12	27	128	137	14.5
99	99	5.8	27	92	46	-44.7*
acebo			TR	ICOR		
Baselin	Endpoin	%	N	Baselin	Endpoin	%
e	t (Mean)	Change	1	e	t (Mean)	Change
(Mean)		(Mean)		(Mean)		(Mean)
710	750	7.2	48	726	308	-54.5*
537	571	18.7	33	543	205	-50.6*
272	271	0.4	48	261	223	-13.8*
27	28	5.0	48	30	36	22.9*
100	90	-4.2	45	103		45.0*
137	142	11.0	45		54	-49.4*
	35 36 3120 7 99 Sacebo Baselin e (Mean) 4 710 537 4 272 4 27 7 100	35 36 3 120 129 7 99 99 Sacebo Baselin Endpoin t (Mean) (Mean) 4 710 750 9 537 571 4 272 271 4 27 28 2 100 90	35 36 4 4 120 129 12 12 12 12 12 12 1	35 36 4 27 27 120	35 36 4 27 34 37 128 27 128 27 128 27 99 99 5.8 27 92	35 36 4 27 34 40 3 120 129 12 27 128 137 99 99 5.8 27 92 46

* = p<0.05 vs. Placebo

The effect of TRICOR on cardiovascular morbidity and mortality has not been determined.

INDICATIONS AND USAGE

Treatment of Hypercholesterolemia

TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below).

Treatment of Hypertriglyceridemia

TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.

Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of TRICOR therapy on reducing this risk has not been adequately studied.

Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia².

The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia.

The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS).

Fredrickson Classification of Hyperlipoproteinemias

		Lipid Elevation				
Type	Lipoprotein Elevated	Major	Minor			
I (rare)	chylomicrons	TG	1 - C			
IIa	LDL	C	-			
Пр	LDL, VLDL	C	TG			
III (rare)	IDL	C, TG	-			
IV	VLDL	TG	1 ∸ C			
V (rare)	chylomicrons, VLDL	TG	1 ↔			

C=cholesterol TG=triglycerides

LDL=low density lipoprotein

VLDL=very low density lipoprotein

IDL=intermediate density lipoprotein

NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle
Changes and Drug Therapy in Different Risk Categories

Risk Category	LDL Goal (mg/dL)	LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL)	LDL Level at Which to Consider Drug Therapy (mg/dL)
CHD [†] or CHD risk equivalents (10-years risk >20%)	<100	≥100	≥130 (100-129:drug optional) ^{††}
2+ Risk Factors (10-year risk ≤20%)	<130	≥130	10-year risk 10%-20%: ≥130 10-year risk <10%: ≥160
0-1 Risk Factor ^{†††}	<160	≥160	≥190 (160-189: LDL-lowering drug optional)

† CHD = coronary heart disease

Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory.

Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary.

After the LDL-C goal has been achieved, if the TG is still >200 mg/dL, non HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category.

CONTRAINDICATIONS

TRICOR is contraindicated in patients who exhibit hypersensitivity to fenofibrate.

TRICOR is contraindicated in patients with hepatic or severe renal dysfunction, including primary biliary cirrhosis, and patients with unexplained persistent liver function abnormality.

TRICOR is contraindicated in patients with preexisting gallbladder disease (see WARNINGS).

WARNINGS

Liver Function: Fenofibrate at doses equivalent to 107 mg to 160 mg TRICOR per day has been associated with increases in serum transaminases [AST (SGOT) or ALT (SGPT)]. In a pooled analysis of 10 placebo-controlled trials, increases to > 3 times the upper limit of normal occurred in 5.3% of patients taking fenofibrate versus 1.1% of patients treated with placebo.

When transaminase determinations were followed either after discontinuation of treatment or during continued treatment, a return to normal limits was usually observed. The incidence of increases in transaminases related to fenofibrate therapy appear to be dose related. In an 8-week dose-ranging study, the incidence of ALT or AST elevations to at least three times the upper limit of normal was 13% in patients receiving dosages equivalent to 107 mg to 160 mg TRICOR per day and was 0% in those receiving dosages equivalent to 54 mg or less TRICOR per day, or placebo. Hepatocellular, chronic active and cholestatic hepatitis associated with fenofibrate therapy have been reported after exposures of weeks to several years. In extremely rare cases, cirrhosis has been reported in association with chronic active hepatitis.

Regular periodic monitoring of liver function, including serum ALT (SGPT) should be performed for the duration of therapy with TRICOR, and therapy discontinued if enzyme levels persist above three times the normal limit.

Cholelithiasis: Fenofibrate, like clofibrate and gemfibrozil, may increase cholesterol excretion into the bile, leading to cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated. TRICOR therapy should be discontinued if gallstones are found.

Concomitant Oral Anticoagulants: Caution should be exercised when anticoagulants are given in conjunction with TRICOR because of the potentiation of coumarin-type anticoagulants in prolonging the prothrombin time/INR. The dosage of the anticoagulant should be reduced to maintain the prothrombin time/INR at the desired level to prevent bleeding complications. Frequent prothrombin time/INR determinations are advisable until it has been definitely determined that the prothrombin time/INR has stabilized.

Concomitant HMG-CoA Reductase Inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.

In a single-dose drug interaction study in 23 healthy adults the concomitant administration of TRICOR and pravastatin resulted in no clinically important difference in the pharmacokinetics of fenofibric acid, pravastatin or its active metabolite 3a-hydroxy iso-pravastatin when compared to either drug given alone.

The combined use of fibric acid derivatives and HMG-CoA reductase inhibitors has been associated, in the absence of a marked pharmacokinetic interaction, in numerous case reports, with rhabdomyolysis, markedly elevated creatine kinase (CK) levels and myoglobinuria, leading in a high proportion of cases to acute renal failure.

The use of fibrates alone, including TRICOR, may occasionally be associated with myositis, myopathy, or rhabdomyolysis. Patients receiving TRICOR and complaining of muscle pain, tendemess, or weakness should have prompt medical evaluation for myopathy, including serum creatine kinase level determination. If myopathy/myositis is suspected or diagnosed, TRICOR therapy should be stopped.

Mortality: The effect of TRICOR on coronary heart disease morbidity and mortality and non-cardiovascular mortality has not been established.

Other Considerations: In the Coronary Drug Project, a large study of post myocardial infarction of patients treated for 5 years with clofibrate, there was no difference in mortality seen between the clofibrate group and the placebo group. There was however, a difference in the rate of cholelithiasis and cholecystitis requiring surgery between the two groups (3.0% vs. 1.8%).

Because of chemical, pharmacological, and clinical similarities between TRICOR (fenofibrate tablets), Atromid-S (clofibrate), and Lopid (gemfibrozil), the adverse findings in 4 large randomized, placebo-controlled clinical studies with these other fibrate drugs may also apply to TRICOR.

In a study conducted by the World Health Organization (WHO), 5000 subjects without known coronary artery disease were treated with placebo or clofibrate for 5 years and followed for an additional one year. There was a statistically significant, higher age-adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p=<0.01). Excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholecystectomy complications, and pancreatitis. This appeared to confirm the higher risk of gallbladder disease seen in clofibrate-treated patients studied in the Coronary Drug Project.

The Helsinki Heart Study was a large (n=4081) study of middle-aged men without a history of coronary artery disease. Subjects received either placebo or gemfibrozil for 5 years, with a 3.5 year open extension afterward. Total mortality was numerically higher in the gemfibrozil randomization group but did not achieve statistical significance (p=0.19, 95% confidence interval for relative risk G:P=.91-1.64). Although cancer deaths trended higher in the gemfibrozil group (p=0.11), cancers (excluding basal cell carcinoma) were diagnosed with equal frequency in both study groups. Due to the limited size of the study, the relative risk of death from any cause was not shown to be different than that seen in the 9 year follow-up data from World Health Organization study (RR=1.29). Similarly, the numerical excess of gallbladder surgeries in the gemfibrozil group did not differ statistically from that observed in the WHO study.

A secondary prevention component of the Helsinki Heart Study enrolled middle-aged men excluded from the primary prevention study because of known or suspected coronary heart disease. Subjects received gemfibrozil or placebo for 5 years. Although cardiac deaths trended higher in the gemfibrozil group, this was not statistically significant (hazard ratio 2.2, 95% confidence interval: 0.94-5.05). The rate of gallbladder surgery was not statistically significant between study groups, but did trend higher in the gemfibrozil group, (1.9% vs. 0.3%, p=0.07). There was a statistically significant difference in the number of appendectomies in the gemfibrozil group (6/311 vs. 0/317, p=0.029).

PRECAUTIONS

gi. e . si

Initial therapy: Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting TRICOR therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (beta-blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy.

Continued therapy: Periodic determination of serum lipids should be obtained during initial therapy in order to establish the lowest effective dose of TRICOR. Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 160 mg per day.

Pancreatitis: Pancreatitis has been reported in patients taking fenofibrate, gemfibrozil, and clofibrate. This occurrence may represent a failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.

Hypersensitivity Reactions: Acute hypersensitivity reactions including severe skin rashes requiring patient hospitalization and treatment with steroids have occurred very rarely during treatment with fenofibrate, including rare spontaneous reports of Stevens-Johnson syndrome, and toxic epidermal necrolysis. Urticaria was seen in 1.1 vs. 0%, and rash in 1.4 vs. 0.8% of fenofibrate and placebo patients respectively in controlled trials.

Hematologic Changes: Mild to moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients following initiation of fenofibrate therapy. However, these levels stabilize during long-term administration. Extremely rare spontaneous reports of thrombocytopenia and agranulocytosis have been received during post-marketing surveillance outside of the U.S. Periodic blood counts are recommended during the first 12 months of TRICOR administration.

Skeletal muscle: The use of fibrates alone, including TRICOR, may occasionally be associated with myopathy. Treatment with drugs of the fibrate class has been associated on rare occasions with rhabdomyolysis, usually in patients with impaired renal function. Myopathy should be considered in any patient with diffuse myalgias, muscle tendemess or weakness, and/or marked elevations of creatine phosphokinase levels.

Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms, and fenofibrate therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed.

Drug Interactions

Oral Anticoagulants: CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED.

HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS).

Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take

TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.

Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration. The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed.

Carcinogenesis, Mutagenesis, Impairment of Fertility: In a 24-month study in rats (10, 45, and 200 mg/kg; 0.3, 1, and 6 times the maximum recommended human dose on the basis of mg/meter² of surface area), the incidence of liver carcinoma was significantly increased at 6 times the maximum recommended human dose in males and females. A statistically significant increase in pancreatic carcinomas occurred in males at 1 and 6 times the maximum recommended human dose; there were also increases in pancreatic adenomas and benign testicular interstitial cell tumors at 6 times the maximum recommended human dose in males. In a second 24-month study in a different strain of rats (doses of 10 and 60 mg/kg; 0.3 and 2 times the maximum recommended human dose based on mg/meter² surface area), there were significant increases in the incidence of pancreatic acinar adenomas in both sexes and increases in interstitial cell tumors of the testes at 2 times the maximum recommended human dose.

A comparative carcinogenicity study was done in rats comparing three drugs: fenofibrate (10 and 70 mg/kg; 0.3 and 1.6 times the maximum recommended human dose), clofibrate (400 mg/kg; 1.6 times the human dose), and gemfibrozil (250 mg/kg; 1.7 times the human dose) (multiples based on mg/meter² surface area). Pancreatic acinar adenomas were increased in males and females on fenofibrate; hepatocellular carcinoma and pancreatic acinar adenomas were increased in males and hepatic neoplastic nodules in females treated with clofibrate; hepatic neoplastic nodules were increased in males and females treated with gemfibrozil while testicular interstitial cell tumors were increased in males on all three drugs.

In a 21-month study in mice at doses of 10, 45, and 200 mg/kg (approximately 0.2, 0.7 and 3 times the maximum recommended human dose on the basis of mg/meter² surface area), there were statistically significant increases in liver carcinoma at 3 times the maximum recommended human dose in both males and females. In a second 18-month study at the same doses, there was a significant increase in liver carcinoma in male mice and liver adenoma in female mice at 3 times the maximum recommended human dose.

Electron microscopy studies have demonstrated peroxisomal proliferation following fenofibrate administration to the rat. An adequate study to test for peroxisome proliferation in humans has not been done, but changes in peroxisome morphology and numbers have been observed in humans after treatment with other members of the fibrate class when liver biopsies were compared before and after treatment in the same individual.

Fenofibrate has been demonstrated to be devoid of mutagenic potential in the following tests: Arnes, mouse lymphoma, chromosomal aberration and unscheduled DNA synthesis.

Pregnancy Category C: Fenofibrate has been shown to be embryocidal and teratogenic in rats when given in doses 7 to 10 times the maximum recommended human dose and embryocidal in rabbits when given at 9 times the maximum recommended human dose (on the basis of mg/meter² surface area). There are no adequate and well-controlled studies in pregnant women. Fenofibrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Administration of 9 times the maximum recommended human dose of fenofibrate to female rats before and throughout gestation caused 100% of dams to delay delivery and resulted in a 60%

increase in post-implantation loss, a decrease in litter size, a decrease in birth weight, a 40% survival of pups at birth, a 4% survival of pups as neonates, and a 0% survival of pups to weaning, and an increase in spina bifida.

Administration of 10 times the maximum recommended human dose to female rats on days 6-15 of gestation caused an increase in gross, visceral and skeletal findings in fetuses (domed head/hunched shoulders/rounded body/abnormal chest, kyphosis, stunted fetuses, elongated sternal ribs, malformed sternebrae, extra foramen in palatine, misshapen vertebrae, supernumerary ribs).

Administration of 7 times the maximum recommended human dose to female rats from day 15 of gestation through weaning caused a delay in delivery, a 40% decrease in live births, a 75% decrease in neonatal survival, and decreases in pup weight, at birth as well as on days 4 and 21 post-partum.

Administration of 9 and 18 times the maximum recommended human dose to female rabbits caused abortions in 10% of dams at 9 times and 25% of dams at 18 times the maximum recommended human dose and death of 7% of fetuses at 18 times the maximum recommended human dose.

Nursing mothers: Fenofibrate should not be used in nursing mothers. Because of the potential for tumorigenicity seen in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug.

Pediatric Use: Safety and efficacy in pediatric patients have not been established.

Geriatric Use: Fenofibric acid is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection.

ADVERSE REACTIONS

CLINICAL: Adverse events reported by 2% or more of patients treated with fenofibrate during the double-blind, placebo-controlled trials, regardless of causality, are listed in the table below. Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.

BODY SYSTEM	Fenofibrate*	Placebo		
Adverse Event	(N=439)	(N=365)		
BODY AS A WHOLE				
Abdominal Pain	4.6%	4.4%		
Back Pain	3.4%	2.5%		
Headache	3.2%	2.7%		
Asthenia	2.1%	3.0%		
Flu Syndrome	2.1%	2.7%		
DIGESTIVE				
Liver Function Tests Abnormal	7.5%**	1.4%		
Diamhea	2.3%	4.1%		
Nausea	2.3%	1.9%		
Constipation	2.1%	1.4%		
METABOLIC AND NUTRITIONAL I	DISORDERS			
SGPT Increased	3.0%	1.6%		
Creatine Phosphokinase Increased	3.0%	1.4%		

SGOT Increased	3.4% **	0.5%
RESPIRATORY		
Respiratory Disorder	6.2%	5.5%
Rhinitis	2.3%	1.1%

Dosage equivalent to 200 mg TRICOR

Additional adverse events reported by three or more patients in placebo-controlled trials or reported in other controlled or open trials, regardless of causality are listed below.

BODY AS A WHOLE: Chest pain, pain (unspecified), infection, malaise, allergic reaction, cyst, hernia, fever, photosensitivity reaction, and accidental injury.

CARDIOVASCULAR SYSTEM: Angina pectoris, hypertension, vasodilatation, coronary artery disorder, electrocardiogram abnormal, ventricular extrasystoles, myocardial infarct, peripheral vascular disorder, migraine, varicose vein, cardiovascular disorder, hypotension, palpitation, vascular disorder, arrhythmia, phlebitis, tachycardia, extrasystoles, and atrial fibrillation.

DIGESTIVE SYSTEM: Dyspepsia, flatulence, nausea, increased appetite, gastroenteritis, cholelithiasis, rectal disorder, esophagitis, gastritis, colitis, tooth disorder, vomiting, anorexia, gastrointestinal disorder, duodenal ulcer, nausea and vomiting, peptic ulcer, rectal hemorrhage, liver fatty deposit, cholecystitis, eructation, gamma glutarnyl transpeptidase, and diarrhea.

ENDOCRINE SYSTEM: Diabetes mellitus

HEMIC AND LYMPHATIC SYSTEM: Anemia, leukopenia, ecchymosis, eosinophilia, lymphadenopathy, and thrombocytopenia.

METABOLIC AND NUTRITIONAL DISORDERS: Creatinine increased, weight gain, hypoglycemia, gout, weight loss, edema, hyperuricemia, and peripheral edema.

MUSCULOSKELETAL SYSTEM: Myositis, myalgia, arthralgia, arthritis, tenosynovitis, joint disorder, arthrosis, leg cramps, bursitis, and myasthenia.

NERVOUS SYSTEM: Dizziness, insomnia, depression, vertigo, libido decreased, anxiety, paresthesia, dry mouth, hypertonia, nervousness, neuralgia, and somnolence.

RESPIRATORY SYSTEM: Pharyngitis, bronchitis, cough increased, dyspnea, asthma, pneumonia, laryngitis, and sinusitis.

SKIN AND APPENDAGES: Rash, pruritus, eczema, herpes zoster, urticaria, acne, sweating, fungal dermatitis, skin disorder, alopecia, contact dermatitis, herpes simplex, maculopapular rash, nail disorder, and skin ulcer.

SPECIAL SENSES: Conjunctivitis, eye disorder, amblyopia, ear pain, otitis media, abnormal vision, cataract specified, and refraction disorder.

UROGENITAL SYSTEM: Urinary frequency, prostatic disorder, dysuria, kidney function abnormal, urolithiasis, gynecomastia, unintended pregnancy, vaginal moniliasis, and cystitis.

OVERDOSAGE

There is no specific treatment for overdose with TRICOR. General supportive care of the patient is indicated, including monitoring of vital signs and observation of clinical status, should an overdose occur. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. Because fenofibrate is highly bound to plasma proteins, hemodialysis should not be considered.

DOSAGE AND ADMINISTRATION

Patients should be placed on an appropriate lipid-lowering diet before receiving TRICOR, and should

^{**} Significantly different from Placebo

continue this diet during treatment with TRICOR. TRICOR tablets should be given with meals, thereby optimizing the bioavailability of the medication.

For the treatment of adult patients with primary hypercholesterolemia or mixed hyperlipidemia, the initial dose of TRICOR is 160 mg per day.

For adult patients with hypertriglyceridemia, the initial dose is 54 to 160 mg per day. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 160 mg per day.

Treatment with TRICOR should be initiated at a dose of 54 mg/day in patients having impaired renal function, and increased only after evaluation of the effects on renal function and lipid levels at this dose. In the elderly, the initial dose should likewise be limited to 54 mg/day.

Lipid levels should be monitored periodically and consideration should be given to reducing the dosage of TRICOR if lipid levels fall significantly below the targeted range.

HOW SUPPLIED

TRICOR™ (fenofibrate tablets) is available in two strengths:

54 mg yellow tablets, imprinted with ≡ and Abbo-Code identification letters "TA", available in bottles of 90 (NDC 0074-4009-90).

160 mg white tablets, imprinted with ≡ and Abbo-Code identification letters "TC", available in bottles of 90 (NDC 0074-4013-90).

Storage

Store at controlled room temperature, 15-30°C (59-86°F). Keep out of the reach of children. Protect from moisture.

Manufactured for Abbott Laboratories, North Chicago, IL 60064, U.S.A. by Laboratoires Fournier, S.A., 21300 Chenôve, France

Made in France

REFERENCES

- 1. GOLDBERG AC, et al. Fenofibrate for the Treatment of Type IV and V Hyperlipoproteinemias: A Double-Blind, Placebo-Controlled Multicenter US Study. Clinical Therapeutics, 11, pp. 69-83, 1989.
- 2. NIKKILA EA. Familial Lipoprotein Lipase Deficiency and Related Disorders of Chylomicron Metabolism. In Stanbury J.B., et al. (eds.): The Metabolic Basis of Inherited Disease, 5th edition, McGraw-Hill, 1983, Chap. 30, pp. 622-642.
- 3. BROWN WV, et al. Effects of Fenofibrate on Plasma Lipids: Double-Blind, Multicenter Study In Patients with Type IIA or IIB Hyperlipidemia. Arteriosclerosis. 6, pp. 670-678, 1986.

Revised: NEW



TRICOR® 48 mg and 145 mg

(fenofibrate tablets)

DESCRIPTION

TRICOR (fenofibrate tablets), is a lipid regulating agent available as tablets for oral administration. Each tablet contains 48 mg or 145 mg of fenofibrate. The chemical name for fenofibrate is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester with the following structural formula:

The empirical formula is $C_{20}H_{21}O_4Cl$ and the molecular weight is 360.83; fenofibrate is insoluble in water. The melting point is 79-82°C. Fenofibrate is a white solid which is stable under ordinary conditions.

Inactive Ingredients: Each tablet contains hypromellose 2910 (3cps), docusate sodium, sucrose, sodium lauryl sulfate, lactose monohydrate, silicified microcrystalline cellulose, crospovidone, and magnesium stearate.

In addition, individual tablets contain:

48 mg tablets: polyvinyl alcohol, titanium dioxide, talc, soybean lecithin, xanthan gum, D&C Yellow #10 aluminum lake, FD&C Yellow #6 /sunset yellow FCF aluminum lake, FD&C Blue #2 /indigo carmine aluminum lake.

145 mg tablets: polyvinyl alcohol, titanium dioxide, talc, soybean lecithin, xanthan gum.

CLINICAL PHARMACOLOGY

A variety of clinical studies have demonstrated that elevated levels of total cholesterol (total-C), low density lipoprotein cholesterol (LDL-C), and apolipoprotein B (apo B), an LDL membrane complex, are associated with human atherosclerosis. Similarly, decreased levels of high density lipoprotein cholesterol (HDL-C) and its transport complex, apolipoprotein A (apo AI and apo AII) are associated with the development of atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C, LDL-C, and triglycerides, and inversely with the level of HDL-C. The independent effect of raising HDL-C or lowering triglycerides (TG) on the risk of cardiovascular morbidity and mortality has not been determined.

Fenofibric acid, the active metabolite of fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.

The effects of fenofibric acid seen in clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of peroxisome proliferator activated receptor α (PPAR α). Through this mechanism, fenofibrate increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III (an inhibitor of lipoprotein lipase activity).

The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles (which are thought to be atherogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. Activation of PPAR α also induces an increase in the synthesis of apoproteins A-I, A-II and HDL-cholesterol.

Fenofibrate also reduces serum uric acid levels in hyperuricemic and normal individuals by increasing the urinary excretion of uric acid.

Pharmacokinetics/Metabolism

Plasma concentrations of fenofibric acid after administration of three 48 mg or one 145 mg tablets are equivalent under fed conditions to one 200 mg capsule.

Absorption

The absolute bioavailability of fenofibrate cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection. However, fenofibrate is well absorbed from the gastrointestinal tract. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate, and 25% was excreted in the feces. Peak plasma levels of fenofibric acid occur within 6 to 8 hours after administration.

Exposure to fenofibric acid in plasma, as measured by C_{max} and AUC, is not significantly different when a single 145 mg dose of fenofibrate is administered under fasting or nonfasting conditions.

Distribution

In healthy volunteers, steady-state plasma levels of fenofibric acid were shown to be achieved within 5 days of dosing and did not demonstrate accumulation across time following multiple dose administration. Serum protein binding was approximately 99% in normal and hyperlipidemic subjects.

Metabolism

Following oral administration, fenofibrate is rapidly hydrolyzed by esterases to the active metabolite, fenofibric acid; no unchanged fenofibrate is detected in plasma.

Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. A small amount of fenofibric acid is reduced at the carbonyl moiety to a benzhydrol metabolite which is, in turn, conjugated with glucuronic acid and excreted in urine.

In vivo metabolism data indicate that neither fenofibrate nor fenofibric acid undergo oxidative metabolism (e.g., cytochrome P450) to a significant extent.

Excretion

After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide. After administration of radiolabelled fenofibrate, approximately 60% of the dose appeared in the urine and 25% was excreted in the feces.

Fenofibric acid is eliminated with a half-life of 20 hours, allowing once daily administration in a clinical setting.

Special Populations

Geriatrics

In elderly volunteers 77 - 87 years of age, the oral clearance of fenofibric acid following a single oral dose of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults. This indicates that a similar dosage regimen can be used in the elderly, without increasing accumulation of the drug or metabolites.

Pediatrics

TRICOR has not been investigated in adequate and well-controlled trials in pediatric patients.

Gender

No pharmacokinetic difference between males and females has been observed for fenofibrate.

Race

The influence of race on the pharmacokinetics of fenofibrate has not been studied, however fenofibrate is not metabolized by enzymes known for exhibiting inter-ethnic variability. Therefore, inter-ethnic pharmacokinetic differences are very unlikely.

Renal insufficiency

In a study in patients with severe renal impairment (creatinine clearance < 50 mL/min), the rate of clearance of fenofibric acid was greatly reduced, and the compound accumulated during chronic dosage. However, in patients having moderate renal impairment (creatinine clearance of 50 to 90 mL/min), the oral clearance and the oral volume of distribution of fenofibric acid are increased compared to healthy adults (2.1 L/h and 95 L versus 1.1 L/h and 30 L, respectively). Therefore, the dosage of TRICOR should be minimized in patients who have severe renal impairment, while no modification of dosage is required in patients having moderate renal impairment.

Hepatic insufficiency

No pharmacokinetic studies have been conducted in patients having hepatic insufficiency.

Drug-drug interactions

In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations.

Potentiation of coumarin-type anticoagulants has been observed with prolongation of the prothrombin time/INR.

Bile acid sequestrants have been shown to bind other drugs given concurrently. Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption. (See WARNINGS and PRECAUTIONS).

Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean C_{max} and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 α -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.

A single dose of pravastatin had no clinically important effect on the pharmacokinetics of fenofibric acid.

Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males. The atorvastatin C_{max} values were not significantly affected by fenofibrate. The pharmacokinetics of fenofibric acid were not significantly affected by atorvastatin.

Clinical Trials

Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb)

The effects of fenofibrate at a dose equivalent to 145 mg TRICOR (fenofibrate tablets) per day were assessed from four randomized, placebo-controlled, double-blind, parallel-group studies including patients with the following mean baseline lipid values: total-C 306.9 mg/dL; LDL-C 213.8 mg/dL; HDL-C 52.3 mg/dL; and triglycerides 191.0 mg/dL. TRICOR therapy lowered LDL-C, Total-C, and the LDL-C/HDL-C ratio. TRICOR therapy also lowered triglycerides and raised HDL-C (see Table 1).

Table 1
Mean Percent Change in Lipid Parameters at End of Treatment[†]

Treatment Group	Total-C	LDL-C	HDL-C	TG
Pooled Cohort				
Mean baseline lipid				
values (n=646)	306.9 mg/dL	213.8 mg/dL	52.3 mg/dL	191.0 mg/dL
All FEN (n=361)	-18.7%*	-20.6%*	+11.0%*	-28.9%*
Placebo (n=285)	-0.4%	-2.2%	+0.7%	+7.7%
Baseline LDL-C > 160 mg/dL		,		
and TG < 150 mg/dL (Type IIa)				
Mean baseline lipid				
values (n=334)	307.7 mg/dL	227.7 mg/dL	58.1 mg/dL	101.7 mg/dL
All FEN (n=193)	-22.4%*	-31.4%*	+9.8%*	-23.5%*
Placebo (n=141)	+0.2%	-2.2%	+2.6%	+11.7%
Baseline LDL-C > 160 mg/dL				
and TG ≥ 150 mg/dL (Type IIb)				
Mean baseline lipid				
values (n=242)	312.8 mg/dL	219.8 mg/dL	46.7 mg/dL	231.9 mg/dL
All FEN (n=126)	-16.8%*	-20.1%*	+14.6%*	-35.9%*
Placebo (n=116)	-3.0%	-6.6%	+2.3%	+0.9%

[†] Duration of study treatment was 3 to 6 months.

In a subset of the subjects, measurements of apo B were conducted. TRICOR treatment significantly reduced apo B from baseline to endpoint as compared with placebo (-25.1% vs. 2.4%, p<0.0001, n=213 and 143 respectively).

Hypertriglyceridemia (Fredrickson Type IV and V)

The effects of fenofibrate on serum triglycerides were studied in two randomized, double-blind, placebo-controlled clinical trials of 147 hypertriglyceridemic patients (Fredrickson Types IV and V). Patients were treated for eight weeks under protocols that differed only in that one entered patients with baseline triglyceride (TG) levels of 500 to 1500 mg/dL, and the other TG levels of 350 to 500 mg/dL. In patients with hypertriglyceridemia and normal cholesterolemia with or without hyperchylomicronemia (Type IV/V hyperlipidemia), treatment with fenofibrate at dosages equivalent to 145 mg TRICOR per day decreased primarily very low density lipoprotein (VLDL) triglycerides and VLDL cholesterol. Treatment of patients with Type IV hyperlipoproteinemia and elevated triglycerides often results in an increase of low density lipoprotein (LDL) cholesterol (see Table 2).

Table 2
Effects of TRICOR in Patients With Fredrickson
Type IV/V Hyperlipidemia

	Type IV/V Hyperhpidemia										
Study 1	Place	ebo.			TRIC	OR					
Baseline TG levels 350 to 499 mg/dL	N	Baseline (Mean)	Endpoint (Mean)	%. Change (Mean)	N	Baseline (Mean)	Endpoint (Mean)	% Change (Mean)			
Triglycerides	28	449	450	-0.5	27	432	223	-46.2*			
VLDL Triglycerides	19	367	350	2.7	19	350	178	-44.1*			
Total Cholesterol	28	255	261	2.8	27	252	227	-9.1*			
HDL Cholesterol	28	35	36	4	27	34	40	19.6*			
LDL Cholesterol	28	120	129	12	27	128	137	14.5			
VLDL Cholesterol	27	99	99	5.8	27	92	46	-44.7*			
Study 2	Plac	ebo			TRIC	COR					
Baseline TG levels 500 to 1500 mg/dL	N.	Baseline (Mean)	Endpoint (Mean)	% Change (Mean)	N	Baseline (Mean)	Endpoint (Mean)	% Change (Mean)			
Triglycerides	44	710	750	7.2	48	726	308	-54.5*			
VLDL Triglycerides	29	537	571	18.7	33	543	205	-50.6*			
Total Cholesterol	44	272	271	0.4	48	261	223	-13.8*			
HDL Cholesterol	44	27	28	5.0	48	30	36	22.9*			
LDL Cholesterol	42	100	90	-4.2	45	103	131	45.0*			
VLDL Cholesterol	42	137	142	11.0	45	126	54	- 49.4*			
											

^{*=} p < 0.05 vs. Placebo

The effect of TRICOR on cardiovascular morbidity and mortality has not been determined.

^{*} p = < 0.05 vs. Placebo

INDICATIONS AND USAGE.

Treatment of Hypercholesterolemia

TRICOR is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below).

Treatment of Hypertriglyceridemia

TRICOR is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.

Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of TRICOR therapy on reducing this risk has not been adequately studied.

Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia².

The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia.

The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS).

Fredrickson Classification of Hyperlipoproteinemias

		Lipid Elevation				
Туре	Lipoprotein Elevated	Major.	or Minor			
I (rare)	chylomicrons	TG	1↔C			
ÌIa	LDL	C	-			
IIb	LDL, VLDL	C	TG			
III (rare)	IDL	C, TG	-			
ÌV	VLDL	TG	↑↔c ↑↔c			
V (rare)	chylomicrons, VLDL	TG	1↔C			

C = cholesterol TG = triglycerides

LDL = low density lipoprotein

VLDL = very low density lipoprotein

IDL = intermediate density lipoprotein

NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories

Risk Category	LDL Goal (mg/dL)	LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL)	LDL Level at Which to Consider Drug Therapy (mg/dL)
CHD† or CHD risk equivalents (10-years risk > 20%)	< 100	≥ 100	≥ 130 (100-129:drug optional)††
2+ Risk Factors (10-year risk ≤ 20%)	< 130	≥ 130	10-year risk 10%-20%: ≥ 130 10-year risk < 10%: ≥ 160
0-1 Risk Factor†††	< 160	≥ 160	≥ 190 (160-189: LDL- lowering drug optional)

CHD = coronary heart disease

Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary.

⁵ Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory.

After the LDL-C goal has, been achieved, if the TG is still >200 mg/dL, non HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category.

CONTRAINDICATIONS

TRICOR is contraindicated in patients who exhibit hypersensitivity to fenofibrate.

TRICOR is contraindicated in patients with hepatic or severe renal dysfunction, including primary biliary cirrhosis, and patients with unexplained persistent liver function abnormality.

TRICOR is contraindicated in patients with preexisting gallbladder disease (see WARNINGS).

WARNINGS

Liver Function: Fenofibrate at doses equivalent to 96 mg to 145 mg TRICOR per day has been associated with increases in serum transaminases [AST (SGOT) or ALT (SGPT)]. In a pooled analysis of 10 placebo-controlled trials, increases to > 3 times the upper limit of normal occurred in 5.3% of patients taking fenofibrate versus 1.1% of patients treated with placebo.

When transaminase determinations were followed either after discontinuation of treatment or during continued treatment, a return to normal limits was usually observed. The incidence of increases in transaminases related to fenofibrate therapy appear to be dose related. In an 8-week dose-ranging study, the incidence of ALT or AST elevations to at least three times the upper limit of normal was 13% in patients receiving dosages equivalent to 96 mg to 145 mg TRICOR per day and was 0% in those receiving dosages equivalent to 48 mg or less TRICOR per day, or placebo. Hepatocellular, chronic active and cholestatic hepatitis associated with fenofibrate therapy have been reported after exposures of weeks to several years. In extremely rare cases, cirrhosis has been reported in association with chronic active hepatitis.

Regular periodic monitoring of liver function, including serum ALT (SGPT) should be performed for the duration of therapy with TRICOR, and therapy discontinued if enzyme levels persist above three times the normal limit.

Cholelithiasis: Fenofibrate, like clofibrate and gemfibrozil, may increase cholesterol excretion into the bile, leading to cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated. TRICOR therapy should be discontinued if gallstones are found.

Concomitant Oral Anticoagulants: Caution should be exercised when anticoagulants are given in conjunction with TRICOR because of the potentiation of coumarin-type anticoagulants in prolonging the prothrombin time/INR. The dosage of the anticoagulant should be reduced to maintain the prothrombin time/INR at the desired level to prevent bleeding complications. Frequent prothrombin time/INR determinations are advisable until it has been definitely determined that the prothrombin time/INR has stabilized.

Concomitant HMG-CoA Reductase Inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.

Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) and pravastatin (40 mg) once daily for 10 days increased the mean C_{max} and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3α-hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively. (See also CLINICAL PHARMACOLOGY, Drug-drug interactions).

The combined use of fibric acid derivatives and HMG-CoA reductase inhibitors has been associated, in the absence of a marked pharmacokinetic interaction, in numerous case reports, with rhabdomyolysis, markedly elevated creatine kinase (CK) levels and myoglobinuria, leading in a high proportion of cases to acute renal failure.

The use of fibrates alone, including TRICOR, may occasionally be associated with myositis, myopathy, or rhabdomyolysis. Patients receiving TRICOR and complaining of muscle pain, tenderness, or weakness should have prompt medical evaluation for myopathy, including serum creatine kinase level determination. If myopathy/myositis is suspected or diagnosed, TRICOR therapy should be stopped.

Mortality: The effect of TRICOR on coronary heart disease morbidity and mortality and non-cardiovascular mortality has not been established.

Other Considerations: In the Coronary Drug Project, a large study of post myocardial infarction of patients treated for 5 years with clofibrate, there was no difference in mortality seen between the clofibrate group and the placebo group. There was however, a difference in the rate of cholelithiasis and cholecystitis requiring surgery between the two groups (3.0% vs. 1.8%).

Because of chemical, pharmacological, and clinical similarities between TRICOR (fenofibrate tablets), Atromid-S (clofibrate), and Lopid (gemfibrozil), the adverse findings in 4 large randomized, placebo-controlled clinical studies with these other fibrate drugs may also apply to TRICOR.

In a study conducted by the World Health Organization (WHO), 5000 subjects without known coronary artery disease were treated with placebo or clofibrate for 5 years and followed for an additional one year. There was a statistically significant, higher age-adjusted all-cause mortality in the clofibrate group compared with the placebo group (5.70% vs. 3.96%, p=<0.01). Excess mortality was due to a 33% increase in non-cardiovascular causes, including malignancy, post-cholecystectomy complications, and pancreatitis. This appeared to confirm the higher risk of gallbladder disease seen in clofibrate-treated patients studied in the Coronary Drug Project.

The Helsinki Heart Study was a large (n=4081) study of middle-aged men without a history of coronary artery disease. Subjects received either placebo or gemfibrozil for 5 years, with a 3.5 year open extension afterward. Total mortality was numerically higher in the gemfibrozil randomization group but did not achieve statistical significance (p=0.19, 95% confidence interval for relative risk G:P=.91-1.64). Although cancer deaths trended higher in the gemfibrozil group (p=0.11), cancers (excluding basal cell carcinoma) were diagnosed with equal frequency in both study groups. Due to the limited size of the study, the relative risk of death from any cause was not shown to be different than that seen in the 9 year follow-up data from World Health Organization study (RR=1.29). Similarly, the numerical excess of gallbladder surgeries in the gemfibrozil group did not differ statistically from that observed in the WHO study.

A secondary prevention component of the Helsinki Heart Study enrolled middle-aged men excluded from the primary prevention study because of known or suspected coronary heart disease. Subjects received gemfibrozil or placebo for 5 years. Although cardiac deaths trended higher in the gemfibrozil group, this was not statistically significant (hazard ratio 2.2, 95% confidence interval: 0.94-5.05). The rate of gall-

bladder surgery was not statistically significant between study groups, but did trend higher in the gemfibrozil group, (1.9% vs. 0.3%, p=0.07). There was a statistically significant difference in the number of appendectomies in the gemfibrozil group (6/311 vs. 0/317, p=0.029).

PRECAUTIONS

Initial therapy: Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting TRICOR therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (beta-blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy.

Continued therapy: Periodic determination of serum lipids should be obtained during initial therapy in order to establish the lowest effective dose of TRICOR. Therapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum recommended dose of 145 mg per day.

Pancreatitis: Pancreatitis has been reported in patients taking fenofibrate, gemfibrozil, and clofibrate. This occurrence may represent a failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect, or a secondary phenomenon mediated through biliary tract stone or sludge formation with obstruction of the common bile duct.

Hypersensitivity Reactions: Acute hypersensitivity reactions including severe skin rashes requiring patient hospitalization and treatment with steroids have occurred very rarely during treatment with fenofibrate, including rare spontaneous reports of Stevens-Johnson syndrome, and toxic epidermal necrolysis. Urticaria was seen in 1.1 vs. 0%, and rash in 1.4 vs. 0.8% of fenofibrate and placebo patients respectively in controlled trials.

Hematologic Changes: Mild to moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients following initiation of fenofibrate therapy. However, these levels stabilize during long-term administration. Extremely rare spontaneous reports of thrombocytopenia and agranulocytosis have been received during post-marketing surveillance outside of the U.S. Periodic blood counts are recommended during the first 12 months of TRICOR administration.

Skeletal muscle: The use of fibrates alone, including TRICOR, may occasionally be associated with myopathy. Treatment with drugs of the fibrate class has been associated on rare occasions with rhabdomyolysis, usually in patients with impaired renal function. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevations of creatine phosphokinase levels.

Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever. CPK levels should be assessed in patients reporting these symptoms, and fenofibrate therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed.

Drug Interactions

Oral Anticoagulants: CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED.

HMG-CoA reductase inhibitors: The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS).

Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.

Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration. The benefits and risks of using TRICOR (fenofibrate tablets) with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Two dietary carcinogenicity studies have been conducted in rats with fenofibrate. In the first 24-month study, rats were dosed with fenofibrate at 10, 45, and 200 mg/kg/day, approximately 0.3, 1, and 6 times the maximum recommended human dose (MRHD) of 145 mg/day, based on mg/meter² of surface area). At a dose of 200 mg/kg/day (at 6 times the MRHD), the incidence of liver carcinomas was significantly increased in both sexes. A statistically significant increase in pancreatic carcinomas was observed in males at 1 and 6 times the MRHD; an increase in pancreatic adenomas and benign testicular interstitial cell tumors was observed at 6 times the MRHD in males. In a second 24-month study in a different strain of rats, doses of 10 and 60 mg/kg/day (0.3 and 2 times the MRHD based on mg/meter² surface area) produced significant increases in the incidence of pancreatic acinar adenomas in both sexes and increases in testicular interstitial cell tumors in males at 2 times the MRHD (200 mg/kg/day).

A 117-week carcinogenicity study was conducted in rats comparing three drugs: fenofibrate 10 and 60 mg/kg/day (0.3 and 2 times the MRHD), clofibrate (400 mg/kg/day; 2 times the human dose), and Gemfibrozil (250 mg/kg/day; 2 times the human dose) (multiples based on mg/meter² surface area). Fenofibrate increased pancreatic acinar adenomas in both sexes. Clofibrate increased hepatocellular carcinoma and pancreatic acinar adenomas in males and hepatic neoplastic nodules in females. Gemfibrozil increased hepatic neoplastic nodules in males and females, while all three drugs increased testicular interstitial cell tumors in males.

In a 21-month study in mice, fenofibrate 10, 45, and 200 mg/kg/day (approximately 0.2, 0.7, and 3 times the MRHD on the basis of mg/meter² surface area) significantly increased the liver carcinomas in both sexes at 3 times the MRHD. In a second 18-month study at the same doses, fenofibrate significantly increased the liver carcinomas in male mice and liver adenomas in female mice at 3 times the MRHD.

Electron microscopy studies have demonstrated peroxisomal proliferation following fenofibrate administration to the rat. An adequate study to test for peroxisome proliferation in humans has not been done, but changes in peroxisome morphology and numbers have been observed in humans after treatment with other members of the fibrate class when liver biopsies were compared before and after treatment in the same individual.

Fenofibrate has been demonstrated to be devoid of mutagenic potential in the following tests: Ames, mouse lymphoma, chromosomal aberration and unscheduled DNA synthesis.

Pregnancy Category C: Safety in pregnant women has not been established. Fenofibrate has been shown to be embryocidal and teratogenic in rats when given in doses 7 to 10 times the maximum recommended human dose (MRHD) and embryocidal in rabbits when given at 9 times the MRHD (on the basis of mg/meter² surface area). There are no adequate and well-controlled studies in pregnant women. Fenofibrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Administration of approximately 9 times the MRHD of 145mg/day of fenofibrate to female rats before and throughout gestation caused 100% of dams to delay delivery and resulted in a 60% increase in post-implantation loss, a decrease in litter size, a decrease in birth weight, a 40% survival of pups at birth, a 4% survival of pups as neonates, and a 0% survival of pups to weaning, and an increase in spina bifida.

Administration of approximately 10 times the MRHD to female rats on days 6-15 of gestation caused an increase in gross, visceral and skeletal findings in fetuses (domed head/hunched shoulders/rounded body/abnormal chest, kyphosis, stunted fetuses, elongated sternal ribs, malformed sternebrae, extra foramen in palatine, misshapen vertebrae, supernumerary ribs).

Administration of approximately 7 times the MRHD to female rats from day 15 of gestation through weaning caused a delay in delivery, a 40% decrease in live births, a 75% decrease in neonatal survival, and decreases in pup weight, at birth as well as on days 4 and 21 post-partum.

Administration of fenofibrate at 9 to 18 times the MRHD to female rabbits caused abortions in 10% to 25% of dams and death in 7% of fetuses at 18 times the MRHD.

Nursing mothers: Fenofibrate should not be used in nursing mothers. Because of the potential for tumorigenicity seen in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug.

Pediatric Use: Safety and efficacy in pediatric patients have not been established.

Geriatric Use: Fenofibric acid is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection.

ADVERSE REACTIONS

CLINICAL: Adverse events reported by 2% or more of patients treated with fenofibrate during the double-blind, placebo-controlled trials, regardless of causality, are listed in the table below. Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.

BODY SYSTEM	Fenofibrate*	Placebo
Adverse Event	(N=439)	(N=365)
BODY AS A WHOLE		
Abdominal Pain	4.6%	4.4%
Back Pain	3.4%	2.5%
Headache	3.2%	2.7%
Asthenia	2.1%	3.0%
Flu Syndrome	2.1%	2.7%
DIGESTIVE		
Liver Function Tests Abnormal	7.5%**	1.4%
Diarrhea	2.3%	4.1%
Nausea	2.3%	1.9%
Constipation	2.1%	1.4%
METABOLIC AND NUTRITIONAL DISORDERS		
SGPT Increased	3.0%	1.6%
Creatine Phosphokinase Increased	3.0%	1.4%
SGOT Increased	3.4% **	0.5%
RESPIRATORY		
Respiratory Disorder	6.2%	5.5%
Rhinitis	2.3%	1.1%

Dosage equivalent to 145 mg TRICOR

Additional adverse events reported by three or more patients in placebo-controlled trials or reported in other controlled or open trials, regardless of causality are listed below.

BODY AS A WHOLE: Chest pain, pain (unspecified), infection, malaise, allergic reaction, cyst, hernia, fever, photosensitivity reaction, and accidental injury.

CARDIOVASCULAR SYSTEM: Angina pectoris, hypertension, vasodilatation, coronary artery disorder, electrocardiogram abnormal, ventricular extrasystoles, myocardial infarct, peripheral vascular disorder, migraine, varicose vein, cardiovascular disorder, hypotension, palpitation, vascular disorder, arrhythmia, phlebitis, tachycardia, extrasystoles, and atrial fibrillation.

^{**} Significantly different from Placebo

DIGESTIVE SYSTEM: Dyspepsia, flatulence, nausea, increased appetite, gastroenteritis, cholelithiasis, rectal disorder, esophagitis, gastroitis, colitis, tooth disorder, vomiting, anorexia, gastrointestinal disorder, duodenal ulcer, nausea and vomiting, peptic ulcer, rectal hemorrhage, liver fatty deposit, cholecystitis, eructation, gamma glutamyl transpeptidase, and diarrhea.

ENDOCRINE SYSTEM: Diabetes mellitus.

HEMIC AND LYMPHATIC SYSTEM: Anemia. leukopenia, ecchymosis, eosinophilia, lymphadenopathy, and thrombocytopenia.

METABOLIC AND NUTRITIONAL DISORDERS: Creatinine increased, weight gain, hypoglycemia, gout, weight loss, edema, hyperuricemia, and peripheral edema.

MUSCULOSKELETAL SYSTEM: Myositis, myalgia, arthritis, tenosynovitis, joint disorder, arthrosis, leg cramps, bursitis, and myasthenia.

NERVOUS SYSTEM: Dizziness, insomnia, depression, vertigo, libido decreased, anxiety, paresthesia, dry mouth, hypertonia, nervousness, neuralgia, and somnolence.

RESPIRATORY SYSTEM: Pharyngitis, bronchitis, cough increased, dyspnea, asthma, allergic pulmonary alveolitis, pneumonia, laryngitis, and sinusitis.

SKIN AND APPENDAGES: Rash, pruritus, eczema, herpes zoster, urticaria, acne, sweating, fungal dermatitis, skin disorder, alopecia, contact dermatitis, herpes simplex, maculopapular rash, nail disorder, and skin ulcer.

SPECIAL SENSES: Conjunctivitis, eye disorder, amblyopia, ear pain, otitis media, abnormal vision, cataract specified, and refraction disorder

UROGENITAL SYSTEM: Urinary frequency, prostatic disorder, dysuria, abnormal kidney function, urolithiasis, gynecomastia, unintended pregnancy, vaginal moniliasis, and cystitis.

OVERDOSAGE

There is no specific treatment for overdose with TRICOR. General supportive care of the patient is indicated, including monitoring of vital signs and observation of clinical status, should an overdose occur. If indicated, elimination of unabsorbed drug should be achieved by emesis or gastric lavage; usual precautions should be observed to maintain the airway. Because fenofibrate is highly bound to plasma proteins, hemodialysis should not be considered.

DOSAGE AND ADMINISTRATION

Patients should be placed on an appropriate lipid-lowering diet before receiving TRICOR, and should continue this diet during treatment with TRICOR. TRICOR tablets can be given without regard to meals.

For the treatment of adult patients with primary hypercholesterolemia or mixed hyperlipidemia, the initial dose of TRICOR is 145 mg per day.

For adult patients with hypertriglyceridemia, the initial dose is 48 to 145 mg per day. Dosage should be individualized according to patient response, and should be adjusted if necessary following repeat lipid determinations at 4 to 8 week intervals. The maximum dose is 145 mg per day.

Treatment with TRICOR should be initiated at a dose of 48 mg/day in patients having impaired renal function, and increased only after evaluation of the effects on renal function and lipid levels at this dose. In the elderly, the initial dose should likewise be limited to 48 mg/day.

Lipid levels should be monitored periodically and consideration should be given to reducing the dosage of TRICOR if lipid levels fall significantly below the targeted range.

HOW SUPPLIED

TRICOR® (fenofibrate tablets) is available in two strengths:

48 mg yellow tablets, imprinted with and Abbo-Code identification letters "FI", available in bottles of 90 (NDC 0074-6122-90).

145 mg white tablets, imprinted with and Abbo-Code identification letters "FO", available in bottles of 90 (NDC 0074-6123-90).

Storage

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Keep out of the reach of children. Protect from moisture.

Manufactured for Abbott Laboratories, North Chicago, IL 60064, U.S.A. by Fournier Laboratories Ireland Limited, Anngrove, Carrigtwohill Co. Cork, Ireland

REFERENCES

- 1. GOLDBERG AC, et al. Fenofibrate for the Treatment of Type IV and V Hyperlipoproteinemias: A Double-Blind, Placebo-Controlled Multicenter US Study. Clinical Therapeutics, 11, pp. 69-83, 1989.
- NIKKILA EA. Familial Lipoprotein Lipase Deficiency and Related Disorders of Chylomicron Metabolism. In Stanbury J.B., et al. (eds.): The Metabolic Basis of Inherited Disease, 5th edition, McGraw-Hill, 1983, Chap. 30, pp. 622-642.
- 3. BROWN WV, et al. Effects of Fenofibrate on Plasma Lipids: Double-Blind, Multicenter Study In Patients with Type IIA or IIB Hyperlipidemia. Arteriosclerosis. 6, pp. 670-678, 1986.

Ref. 03-5344-R1

Revised: November, 2004 04K-030-F542-1 MASTER

04K-030-F534-1

ABBOTT



PRINTED IN U.S.A.

RESCRIPTION

Antara (tendibrate) Capsules, is a lipid regulating agent available as capsules for oral administration. Each capsule contains 43 mg, 87 mg, or 170 mg of nicronized tendibrate. The chemical name for fenotizate is 2-14-14-chloroberusyll phenoxyl-2-methyl-proparatic acid. 1-methylethyl ester with the following structural formula:

ا بد ن

The empirical formula is $C_{20}H_{20}O_{4}Cl$ and the molecular weight is 350.83; tenof-trate is assoluble in water. The metting point is 79° -92°C. Fenofibrate is a white solid which is stable under ordinary conditions.

Inactive Ingredients: Each gelatin capsule contains sugar spheres, hypronellose, sodium buryl safate, danethicone, simethicone, and talo. The gelatin capsules also contain sudur dioxide, titanium dioxide, yelkow iron calde, hidlyo carmine FO&C Blue #2, DAC Yellow #10 and black infl. CLINICAL PHARMACOLOGY

CLINICAL PHARMADULOY

A variety of Cincal studies have demonstrated that elevated levels of total chokstord (total-C), low density lipoprotein chokstord (D.L.C.), and apolipoprotein (B.D.C.), and apolipoprotein (B.D.C.), and apolipoprotein (B.D.C.), and apolipoprotein (B.D.C.), and apolipoprotein chokstord (B.D.C.) and its transport complex, epolipoprotein A top A1 and apo A11) are associated with the development of alternosdensis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of foliation. C.D.C. and trightcendes, and inversely with the level of IBD.C. The independent effect of reising HDL-C or lowering trightcendes (TG) on the risk of cardiovascular morbidity and mortality has not been determined.

Fenofibric acid, the active metabolite of (enroflorate, produces reductions in total chokesterol, LDL chokesterol, apolipoprotein B, total trighty-

erides, and biolyceride rich lipoprotein (M.DL) in treated patients, in addition, treatment with terrofibrate results in increases in high o

erios, and higheride rich (poprotein (N.D.) in treated patients, in addition, treatment with terrotionate meads in increases in high density toporotin (100) and approfessions appeal and part and an appeal of the patients and seen an clinical practice have been explained in vivo in transgenic mice and in vitro in human hepatocyte cultures by the activation of perceisions protiterater activated receptor of PPARLs.)

Through this mecticalism, involutivate increases lipoyais and elimination of triphyceide-rich particles from plasma by activating inportein lipase and reducing production of apportein C-111 (an inhibitor of lipoprotein lipase activity). The resulting lain highers less produces and tradeorny production of apportein C-111 (an inhibitor of lipoprotein lipase activity). The resulting lain highers produces are catalogical activation in the size and compression of LDI from small, dense particles (which are of trought to be attenogenic due to their susceptibility to oxidation), to large buoyant particles. These larger particles have a greater affairly for crokesterol receptors and are cataloxical anguly Advanction of PPARLs place induces an increase in the synthesis of appropriate ALI-A-II and MDL-A-Ordesterol.

Fendinate above clusters summaric acid levels in hyponomenate and normal individuals by increasing the universe exception of uric acid.

Pharmacokinetics/Nietabolism Plasma concentrations of fenolistic acid after multiple cose administration of Antera 130 mg capsules are equivalent, under low-fat fed conditions, to 200 mg fenofibrate capsules

Asserption
The aboutine bioarelizability of tenofibrate connot be determined as the compound is virtually insoluble in aqueous media suitable for injection. However, funcifiente is well absorbed from the pastrointestinal tract, Following or all administration in healthy volunteers, approximately 60% of a single does of radiobacked tenofibrace appeared in rule, primarily as ferrofibra exist on its equations in rule, primarily as ferrofibra exist on its equations rulpage, and 25% was excreted in the faces. Peak plasma levels of ferrofibric exist from Antara occur within 4 to 8 hours after administration. There was test than does-proportional increase in the systemic exposure of tenofibric axial from three strengths (45 mg, 87 mg, and 130 mg) of Antara under fasting conditions.

Does of the out-of-three strengths of 43 mg.

es of two- or three-capsules of 43 mg Antara given concurrently were dosc-countratent to single-capsule doses of 67 mg and 130 mg, respectively.

The enterf of biosphion of acid was unaffected when Antara was taken either in fasted state or with a low-fat meal. However, the C, Antara Increased in the presence of a low-fat meal. I_{max} was unaffected in the presence of a low-fat meal. In the presence of a hig meal, there was a 26% increase in AUC and 100% increase in C_{max} of fenditivic acid from Antara relative to fasting state.

in healthy volunteers, steady-state plasma levels of tempforic acid were shown to be achieved within a week of dosing and did not demonstrate accumulation across lime following multiple dose administration. Serum protein binding was approximately 99% in normal and hyperinidemsc subjects

Metaholism Following oral administration, fenolibrate is rapidly hydrotyzed by esterases to the active metabolite, fenolibric acid; no unchanged tenofi-

brate is detected in plearna.

Fenditive and is primarily confugated with glucuronic acid and then exceed in our e. A small enount of tendition acid is reduced at the cathony motivy to a benziphotol metabolits which is, in turn, conjugated with glucuronic acid and exceeded in urine.

In who metabolism data indicate that neither fenditional or fenditivities acid indexes outdative metabolism (e.g., cytochrome P450) to a

significant extent.

Excretion
After discorption, terrofforate is mainly excreted in the urine in the form of metabodies, primarily terrofforic acid send terrofforic acid glucuronide.
After administration of radiolabelled terrofforate, approximately 60% of the dose appeared in the urine and 25% was excreted in the leces.
Fenoribrate acid from Antara is eliminated with a half-life of 23 hours, allowing once daily administration in a clinical setting.

Special Populations certaines

In electry countriers 77–87 years of age, the oral clearance of tenofibric acid tobowing a single oral doss) of fenofibrate was 1.2 L/h, which compares to 1.1 L/h in young adults. This indicates that a similar dossige regimen can be used in the effect, without increasing accumulation of the drug or metabolities.

Antere has not been investigated in adequate and well-controlled trials in pediatric patients.

No pharmacokinetic difference between males and temales has been observed for lesofibrate.

have. The influence of race on the pharmocokinetics of fenofibrate has not been studied; however, fenofibrate is not metabolized by enzymes known for exhibiting dise-ethnic variability. Therefore, inter-ethnic pharmocokinetic differences are very unlikely. Remain insufficiency.

Renal insufficiency
In a study in patients with severe renal impairment (creatinine clearance <50 mL/min), the rate of clearance of enorithric acid was greatly reduced, and the compound occumulated during durant cleasance. However, in patients having moderate renal impairment (creatinine clearance of 50 mL/min), the rate of 50 mL/min), the rate of clearance of 50 mL/min), the rate of 50

Hepatic insufficiency
No pharmacokinetic studies have been conducted in patients having bepatic insufficiency. Drug-drug interactions

In vitro studies using human liver microsomes indicate that tenofityrate and fenolithic acid are not inhibitions of cytochrome (CYP) P450 iso-forms CYP3A4, CYP206, CYP2E1, or CYP1A2. They are weak inhibitors of CYP2C19 and CYP2A6, and mikit-to-moderate inhibitions of CYP2C9

at merapence concurrances.

Potentation of counsarin-type anticoogustats has been observed with prolongation of the protherantion the PNR.

Bits acid sequestrants have been shown to bind other drups given concurrently. Therefore, terrolibrate of out-of-between at least 1 hour before or 4-6 hours after a bits acid binding repin to avoid impeding its absorption (see WARNINSS and PRECAUTIONS).

Clinical Trials

Hypercholesterolemia (Heterozygous Familial and Nontamilial) and Mixed Dystinidemia (Frodrickson Typos 11a and 11b)

The effects of fenofibrate at a cocse equivalent to 130 mg Antara per day were assessed from four randomized, placebo-controlled, double-blind, parallel-group studies including patients with the following mean baseline tipd, values, total-C 305.9 mg/dL; DIL-C 213.8 mg/dL; HUL-C 52.3 mg/dL; and triphycarides 191.0 mg/dL. Perofibrate therepy lowered LDL-C, Total-C, and the LDL-CHOL-C ratio. Ferrofibrate there apy also lowered triphycarides and raised HUL-C (see Table 1).

freatment Group	Total-C	LOL-C	HDL-C	TG
Pocied Cohort Mean baseline lipid values (n=646) All FEN (n=361) Placebo (n=285)	306.9 mo/d. -18.7% -0.4%	213.8 mg/dL -20.6%	52.3 mg/d +11.055* +0.7%	191.0 mg/di. -28.9% +7.7%
kaseline LDL-C >160 mg/dL and TS <150 mg/dL (Type 11e) Mean baseline (jaid values (n=234) All FEN (n=193) Phacebo (n=141)	307.7 mg/dL -22.4%* +0.2%	227.7 mg/dL -31.4%* -2.2%	58.1 mg/gl. +9.8%* +2.6%	101.7 mg/dL -23.5%* +11.7%
Secretine LDL-C > 150 mg/dL and TG±150 mg/dL (Type 11b) Mean baseline libid values tn=242) All FEN (n=126) Pracebo (n=116)	312.8 mg/dL -16.6% -3.0%	219.8 mg/d_ -20.1%* -6.6%	46.7 mg/dL +14.5% +2.3%	231.9 mg/dL -35.9%*

p≈<0.05 vs. placebo

In a subset of the subjects, measurements of apo B were conducted. Feroilibrate treat ment significantly reduced upo B from baseline to ond-point as compared with placebo (-25,1% vs. 2.4%, p-<0.0001, n=213 and 143 respectively).

Antara[™]

(fenofibrate) Capsules

Hypertriglyceridemia (Fredrickson Type IV and V) The effects of ferrofibrate on serum triglycerises Hypertrippocratema greanesson type IV and V). The effects of terror present contents of terror present support of terror present of the terror present of te Epografein (LDL) cholesteral (see Table 2)

Table 2.

Effects of Fenofibrate in Patients With Fredrickson Type IV/A: HyperlipIdemia								
Study 1		Pla	cebo		Fenofibrate			
Basei≊ra TG levels 350 to 499 mg/di.	N	Baseline (Mean)	Endpuint (Mean)	% Drunge (Moard	H	(Saseline (Maan)	Endpoint (Mean)	% Change (Mean)
Trigiyoerides	28	449	450	-0.5	27	432	223	-46.2*
VLDt. Triglycerides	19	367	350	2.7	19	350	178	-44.1*
Total Choiesterol	28	255	761	2.8	27	252	227	-9.1°
HDL Cholesterol	28	35	J6	4	27	34	40	19.6*
LDI Cholesterol	/8	120	129	12	27	128	137	14.5
VLDL Cholesterol	27	39	39	5.8	27	92	46	-44.7*
Study 2		Plac	ebo			Fenaf	ibrate	
Bassime TG levels 500 to 1500 mg/di,	N	Baseline (Mean)	Enopoint (Mean)	% Change (Meard	Ħ	Baseline (Mean)	Endpoint (Mean)	% Change (Mean)
Triglycerides	14	710	750	7.2	48	726	308	-54.5 *
VLDL Trighyceristes	23	537	571	18.7	33	543	205	-50.6*
Total Cholesterol	44	272	:71	9.4	48	261	223	-13.8°
HDL Cholesterol	44	27	28	5.0	48	30	36	22.9*
LDL Cholesterol	42	100	90	-4.2	45	103	131	45.0*
VLDL Cholesterol	42	137	142	11.0	45	125	54	-49.4*

⁼p<0.05 vs. piacebo

The effect of tenolibrate on cardiovascular morbisity and mortality has not been determined.

INDICATIONS AND USAGE Treatment of Hypercholes

Affairs is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Traplyceridas, and Apo B, and to Increase HDL-C in adult patients with primary hyperthoscientemb or mixed dystipidems (Fredrickson Types II) and III). Lipid-elbring egents should be used in addition to a diet restricted in abstracted let and ordestered when reponse to det and non-pharmacological interventions alone has been inadequate (see National Chokesteryl Education Program (NCEP) Treatment Guidelines, below).

addition to a diet restricted in saturated fat and christered when response to det and non-pharmacological interventions alone has been inadequate (see National Christered Education Program (IDCP) (restment devidence, between Intervention Antara is also indicated as adjustment enterpy to diet is instalment of adult patients with hypertriphycoridemia (Fredrickvin Types IV and V hypertriphycoridemia). Improving glycemic control in diabetic patients drawing lasting chylomiconamia will usually reduce fashing triphycerides and eliminate chylomiconomia thereby chyloting the need for platimacologic intervention. Markedy devaded levels of ucuma the hypertriphycoride (p. 2-2,000 mg/d.), may increase the risk of developing paracrealitis. The effect of Antara therapy on reducing this risk has not been adequately studeed. Drug therapy is not indicated for patients with Type I hypertriphycroteinemia, who have elevations of chylomicrons and plasma trighycerides, but who have normal levels of very low density tipogratien (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types 1, IV and V hypertriphycroteinemia.

The initial teatment for dystigatemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess also-holic intoka may be important factors in hypertriphyce-teemia and chould be addressed prior to any drug therapy. Physical exercise can be an important amblary measure. Dissesses on the budy of hypertriphemia, and as hypodryroidann or diabetes refress to subside for and adequately treated, Edinogen therapy. But histarde districts and beta-blockers, is sometimes associated with measure rises in plasma riphyce-rides, specially in authors which familia hippert disponitionals, in sometimes associated with measure rises in plasma riphyce-rides, specially in authors with familia hippert disponitionals. In the decision is made to use drugs, the patient should be instructed that this does not reduce the Importance of adhering to del (see WARRINGS and PRE

Fredrickson Classification of Hypertipoproteinemias						
Туре	Lipoprotein Elevated	Major Lipi	d Elevation Minor			
I (rare)	Chylomicrons	TG	1 +C			
l1a	IDL	C	=			
IID	LDL, VLDI	C	TG			
LII (rare)	IDL	C, TG	-			
IV.	VA.DL	TG	1 ↔ C			
V frarei	Chylomicrons, VLDL	TG	1 ↔			

C-chriesteni

C=0:005:00 TG=triglycerices LDL=low density lipoprotein

ity incanuteir

NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories

LDL Goaf (mg/dL)	Therapeutic Lifestyle Changes (mg/dL)	Which to Consider Drug Therapy (mg/dl.)
<100	00)د	≥130 (100-129: drug option#) ^{††}
e/(30	≥13 0	10-year risk 10-20%: ≥130 10-year risk <10%: ≥160
. 160	≥160	±190 (160-159: LDL-lowering drug optional)
	(mg/dL) <100 <130	(mg/dL) (mg/dL) <100 ±100 <130 ±130 <160 ±160

CHD-corocrary heart discrese.
 Some authorities recommend use of LDL-towering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by the repeated literate changes. Others profer use of change had primarily modify brighterides and NDL-C, e.g., nicothic acid or fibrate. Chincial plagment also may cell for deferring drug therapy in this subcategory.
 Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not

After the LDL-G goal has been achieved, if the TG is still > 200 mg/dl., nun-HDL-C (total-C minus HDL-C) becomes secondary target of therapy, Non-HDL-C goals are set 30 mg/dl. higher tran LDL-C goals for each risk category.

CONTRAINDICATIONS

count retroctations of a patients who entitle hypersensitivity to ferrotizate, including primary bitary carhosis, and patients with reposition severe runal dystruction, including primary bitary carhosis, and patients with unexplained persistent liver function abnormality.

Ferrotizatio is contrainducated in patients with premising galloladder disease (see WAPMINGS).

WARRINS
Liver Functions Fencitarate at doors equivalent to 87 mg to 130 mg Antera per day has been associated with increases in serum transam-nases [AST (SGOT) or ALT (SGPT)]. In a pooled analysis of 10 placebo-controlled triats, increases to >3 times the upper limit of normal occurrence in 3.3% of patients being tenoristrate versus 1.1% of patients betaeted with parabolo.
When transaminase determinations were tolerwise deter after obsorptionation of nestment or during continued treatment, a return to nor-mal limits was usually observed. The incidence of increases in transaminases related to tenofibrate therepy appear to be dose related, in an evenek dose-ranging study, the encidence of ALT or AST leavations to oil least free times the upper limit of normals 13% in patients recarring dosepts equivalent to 87 mg to 130 mg Antera per day and was 0% in those receiving dosepts equivalent to 43 mg or less Antera per day, or phorobo, hipsatoc-likuts, chronic active and choisestatic hepotitis associated with terreflorate therapy have been reported after expo-sares of weeks to sureral years, in extremely ner cause, certains has been reported in association with chronic active hepatids. Regular periode monitoring of liver hanchini, inducting serium ALT (SGPT) should be performed for the duration of therapy with Antera, and therapy discontinual of anymym bereb period above three times the normal limit.

Choletthiasis: Fenofitirate site of surface are invalidated. Anterio therapy value to decombined in additional arms of normal.

choleithiasis is suspected, quibladder utudies are audicated. Antara therapy chould be discontinued if gallistones are

0) 4 %

ø

(fenofibrate) Capsules

Concomitant Oral Anticoagulants: Caption should be exercised when anticoagular is are given in conjunction with Antara because of this potentiation of counsaria-type anticoagularis in prolonging the protinoman time aNR The dissipil of the anticoagulari should be recliced to maintain the protinomation time/RR at the desired level to proven the eating complications. Frequent prothermain should be recliced to maintain the protinomation time/RR at the desired level to proven the eating complications. Frequent prothermain should be avoided unless determinables as a extraints in light levels is likely to obverigh the increased inso this lay constitution. In a single-dose drug interestion tasty in 23 healthy adults the concomitant administration of fundionate and pravastatin insuling the three and properties in the pharmacolisation of interesting and provided in no chirality important difference in the pharmacolisation of conformation of translations and provided in no chirality important difference in the pharmacolisation of the properties
PRECAUTIONS

PRIECAUTIONS
Initial Therapy: Laboratory studies should be done to excertain that the lipid levels are consistently abnormal before Instituting Antora therapy. Every attempt should be made to control serum lipids with appropriate dist, exercise, weight lass in those patients, and control or any medical problems such as disbets meltibus and hypothyridism that are contributing to the lipid abnormals. Medications known to exacertable hyperhigh certifiemia (beta-blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consider-

to exceptible hypertrightentidemia (beta-blockers, thiazides, estrogens) should be discontinued or unanged it possible prior to considerable therapy. Province determination of serum lipids should be obtained during initial therapy in order to establish the lowest effective does of Antara. Threapy should be withdrawn in patients who do not have an adequate response after two months of treatment with the maximum economistical dries of 133 mpc dright. Parcreatitis: Parcreatitis has been reported in patients taking fenotiarotis, genfilm ris, and clotiforate. This occurrence may represent a faiture of efficacy in patients with severe hypertrighyceridemia, a direct drug effect, or a secondary phenomenon mediated through believ tract stone or studge formation with obstruction of the common bile dust.

Hypertensity Reactions: Anath hypertensity reactions including severe skin rishes requiring patient hospitalization and treatment with steroids here occurred very rarely during treatment with steroids recovering and turk expendental necessary for the province of the continue of t

atologic Changes: Mild to moderate hemoglobin, hematocrit, and white blood cell decreases have been observed in patients follow

remainings changes will be most in the members, and write bood or il decreases have been observed in policies following indication of broofbiate therapy, however, these levels staffice during the picture of which some propried thromborytopenia and agranulocytosis have been received during post-marketing our eithand outside of the U.S. Periodic blood counts are recommended during the first 12 monits of Artara administration.

Skeletal Missole: The use of fibrates alone, including Antara, may occasionally be associated with myopethy. Treatment with drugs of the fibrate dash she been associated on are occasions with rabbornyolysis, usually in patients with impaired renal function. Mayoptity should be considered in any patient with diffuse mystiguia, muscle tendemess or weatness, and/or marked elevations of creating proprohibitions of 1000 tender. phokinase (CPK) levels.

Patients cloud the advised to report promptly unemplained muscle point, tendemess or weakness, particularly if accompanied by makins or fever. CPK levels should be assessed in patients reporting these symptoms, and tenditivate therapy should be discontinued if marked-y elevated CPK levels occur or myopathy is diagnosed. or fever CPK levels should be asses-

Drug Interactions:

brate. Repartic neophastic nodules were increased in makes and ternales threated with gemilibraril while testicular introstitial cell tumors were increased in makes on all three drugs.

In a 21-month study in mice at doses of 10, 45, and 200 mg/kg approximately 0.2, 17 and 3 times the maximum recommended human dose on the basic of imgreeder gurface area), there were statistically significant increases in liver occiniona at 3 times the maximum recommended human dose in both makes and lemales. In a second 18-month study at this same doses, there was a significant increase in liver continents in make mice and the elements in termals mice at 3 times the maximum recommended human dose. Electron microcopy studies have demonstrated perodoxomal proliferation following fenditates administration to the rat. As adequate study to test for peroxisome proliferation from in humans have been done, but changes in peroxisome morphology and numbers have been observed in humans after treatment with other members of the fitnate class when I ver biopases were compared before and after breatment in the same individual.

Fenofibrate has been demonstrated to be devoid of mutagenic potential in the following tests: Ames, mouse lymphoma, chromosomal

Ferndibrate has been demonstrated to be deroid of mutagenic potential is the following tests: Ames, mouse lymphoma, chromosomal aberration, and outscheduled DNA symbiosis.

Pregnancy Category C. Ferndibrate has been shown to be embryocidal and terefogenic in rats when given in doses 7 to 10 times the maximum recommended human dose and embryocidal in rabbits when given at 9 times the maximum recommended human dose (on the basis of imprimedr' surface area). There are no acceptate and well-controlled studies in pregnant women. Fendibrate should be used during pregnancy only if the potential benefit justifies the potential rick to the felus.

Administration of 9 times the maximum recommended human dose of fendibrate to temple rats before and throughout gestation caused 100% of dama to detay delivery and resulted in a 60% increase in post-implentation loss, a decrease in their size, a decrease in both weight, a 40% survival of pups at birth, a 4% curvival of pups ac neonotes, are a 0% curvival of pups to wearing, and an increase in store and increase in store and increase in store are desired.

In spinal biffide.

Administration of 10 times the maximum recommended human doze to furnate rats on days 6-15 of gestation occused an increase in gross, viscoral and exhetal findings in lethuses (correct head/funched shoulders/rounded body/shormor chest, kyphosis, stunted fetuses, exhapated stemal ribs, mathemed dismetrale, exha foramen in polatine, misstagen ventebrae, cupernumerary ribs. Administration of 7 times the maximum recommended human dose to female rats hom day 15 of gestation through searing caused a delay in delivery, 4 47% decrease in like births, a 75% decrease in neonatal survival, and decreases in pup weight, at birth as well as on days 4 and 2 post-parture.

Administration of 9 and 18 times the maximum recommended human dose to female rabbits caused obortions in 10% of dams at 9 times and 25% of dams at 18 times the maximum recommended human dose and 6-ath of 7% of fetuses at 18 times the maximum recommended human dose.

Ministria matters asset should not be used in nursing mothers. Because of the potential for tumorigenicity seen in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug.

Pediatric User Sofety and efficacy in pediatric potients have not been established.

Antara[™] (fenofibrate) Capsules

Gertatric Use: Fenotibric acid is known to be substant ally expreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaged renal function. Because elderly patients are more libraly to have decreased renal function, care should

ADVENSE REACTIONS
CLINICAL: Adverse events reported by 2% or more of patients treated with fundificate during the double-blind, place? o-controlled trials, regardless of causality, are lasted in the table below. Anverse events led to discumination of treatment in 5.1% of potients treated with fenditizate and in 3.0% in called with placebo. Increases in liver function furth verse were the most frequent events, causing discontinuation of lengibrate treatment in 1.6% of patients in double-blind trials.

BODY SYSTEM Adverse Event	Fenofibrate* (N=439)	Ptacebo (N=365)	
BODY AS A WHOLE		**************************************	
Abdominal Pain	4.6%	4.4%	
Back Pain	3.4%	2.5%	
Headache	3 2%	2.7%	
Asthenia	2.1%	3.0%	
Fiu Syndrome	. 2.1%	2.7%	
DIGESTIVE			
Liver Function Tests Abnormal	1.5%**	1.4%	
Disorhea	2.3%	4.1%	
Kausea	2.3%	1.9%	
Constinution	4.1%	1.4%	
METABOLIC AND			
NUTRITIONAL DISCRIDERS			
SGPT Increased	3.0%	1.6%	
Creatine Phosphokinase Increased	3.0%	1.4%	
SGOT Increased	1,4%**	0.5%	
RESPIRATORY			
Respiratory Disorder	6.2%	5.5%	
Rhinitis	2.3%	1.1%	

Dosace equivalent to 130 mg Antara

"Sprillantly different from planeto
Additional adverse events reported by three or more patients in placebo-untrolled trials or reported in other controlled or open trials,
regulates of causably are listed below.

800Y AS A WHOLE: Chest pain, pain (unspecified), infection, mainise, allerge, reaction, cyst, fernia, fever, photosens-tivity reaction, and

CARDIOVASCULAR SYSTEM: Angina pectoris, hypertension, vasuolitatation, coronary artery disorder, electrocardiogram abnormal, ventricu-

CARDIVISCELAR SYSTEM Anging pectoris, hypertenson, vasualistation, coronary artary disorder, electrocardiogram abnormal, varificular extrasystates, impocardal interde, peripheral vascular disorder, migratine, various vem, cardiovascular disorder, hypotension, poblitation, vascular disorder, armytinnia, pritabilis, techycardia, entrasystates, and other librilisticm.

DIGESTIVE SYSTEM Dyspepes, filterinera, enusea, increased apportice, quastroentenits, choleithilasis, roctal disorder, esophagista, gestritik, colidis, postendaria ulcer, reauses and vomiting, peptic ulcer, roctal hemocrating, liver latty deposit, cholecystitis, enuctation, gamma glutomyl transpeptidase, and diomhea.

EMDICRIE SYSTEM Diabetes mellitus.

HEMBOLICARD IMPRIMITE SYSTEM Amenia, toukopenia, ecchymosis, cashophilia, lymphadenopathy, and thrombocytopenia.

METABOLICARD MITERITIONAL DISORDERS: Creatinine increased, wwight gain, hypoglycemia, gout, weight loss, edema, hyperuricemia, and certheren deterna.

perijindra cuerra. MUSCIA.OSKELETAL SYSTEM Myositis, myalqia, arthralqia, arthralki, tenosynovitis, joint disorder, arthrosis, leg cromps, bursitis, and

myasthenia. NERVOUS SYSTEM: Dizziness, insumnla, depression, vortipo, libido docreasod, andiety, parestresia, dry mouth, hypertonia, nervo

ratia, and sometimes.

RESPRANCING STSTEM: Pharyngitis, brunchiis, cough eurosased, dysprea, asthma, presumonia, bryngitis, and sinasitis.

RESPRANCING STSTEM: Pharyngitis, brunchiis, cough eurosased, dysprea, asthma, presumonia, bryngitis, and sinasitis.

SRM AND APPENDACES. Read, pruffus, screma, herper mister, urtitratia, anne, sweating, langel dermatitis, skin disorder, aloperia, contact dermatitis, herpes simplex, manulopopular trash, ratil disorder, and clin utcer.

SPECIAL SERSE Conjunctivis, eye disorder, armbyogue, ere pain, roths media, abrommal vision, catarect specified, and refraction disorder.

LEGICATION STSTEM: University frequency, prostatic oncorder, dyouria, kidney function abnormal, urolithicsis. Synecomastia, unintended pregnancy, raginal monification and cystilis

OVERDOSAGE

There is no specific treatment for overdose with Ankara. General supportive care of the patient is indicated, including monitoring of vital signs and observation of direct status, should an overdose occur. It indicated, elimitation of unabsorbed drug should be achieved by enesits or gastic trange; usual precautions should be observed to maintain the airway. Because fenolibrate is highly bound to plasma proteins, hemodialysis should not be considered.

DOSAGE AND ADMINISTRATION

Patents should be places on an appropriate lipid-lowering diet before receiving Antara, and should continue this diet during treatment with Antara. Antara capsules should be taken with mexis, thereby optimizing the bloavallability of the medication.

For the treatment of adult patients with primary trepercholesterolemia or mixed hyperspidentia, the willtel dose of Antara is 130 mg

er day.

For adult patients with hypertrepyceridemia, the initial dose is 43 to 130 mg per day. Dosege should be individuelized according to electrit response, and should be adjusted if necessary following repeat high determinations at 4 to 8 week intervals. The maximum dose is 130 mg per day.

Treatment with Antara should be initiated at a dose of 43 mg/day in patients having impaired renal function, and increased only fiter evaluation of the effects on renal function and high levels at this duze, in the effecty, the initial dose should likewise be limited.

As markets.

to 43 mg/day.

Lipid leve's should be monitored periodically and consideration should be given to reducing the dosage of Antara if lipid tevels tall sig-

officantly below the targeted rance

HOW SUPPLIED

Antara (lenofibrate) Capsules, is available in three shengths:

43 mg capsules, imprished with "43" and a segmented band, on the light green cap and "ANTARA" with the Relient logs on the white to off-white body, available in buttles of 30 (NDC = 65726-401-10) and 100 (NDC = 65726-401-25).

87 mg capsules, imprinted with 187° and a segmented band, on the dark green cap and "ANTARA" with the Rekent logo on the light green body, available in bottles of 30 (NDC # 65726-402-10) and 100 (NDC # 65726-402-25).

130 mg capsules, Imprinted with "130" and a permented band, on the dark green cap and "ANTARA" with the Relant logo on the white body, available in bottles of 30 (NDC # 65725-403-1)% and 100 (NOC # 65726-403-25).

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-56°F) [see USP Controlled Room Temperature] in a tightly closed container.

REFERENCES:

1. GOLDBERG AC, et al. Fenotibrate for the Treatment of Type IV and V Hypertipoproteinemias: A Deuble: Blind, Placebri-Controlled Multicenter US Study. Clinical Therapeutics, 11, ppg 40-83, 1989.

NGOLLA EA. Femilial Lipoprotein Lipase Deficiency and Related Disorders of Chytomicton Metabolism. In Stanbury J.B., et al. (eds.): The Metabolic Basis of Inherited Disease. 5th edition. McGraw-Hill, 1983. Chap. 30, pp. 622-642.

BROWH WY, et al. Effects of Fenoliticate on Pleases Lipida: Double-Birid, Multicenter Study in Patients with Type 11A or 11B Hyperlipidemia. Arteriosciencia: 6, pp. 679-678, 1986

Rx Only March 2005



Manufactured for: Reliant Pharmaceuticata, Inc Liberty Corner, NJ 07938, USA

Ethypharm Industries Le Grand Quevilly, France Address Medical Inquiries to

Relant Pharmaceuticals, Inc. Medical Affairs Liberty Corner, NJ 07938, USA

O 2005 Reliant Pharmaceuticals, Inc. PRINTED IN U.S.A.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

□ BLACK BORDERS
□ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
□ FADED TEXT OR DRAWING
□ BLURRED OR ILLEGIBLE TEXT OR DRAWING
□ SKEWED/SLANTED IMAGES
□ COLOR OR BLACK AND WHITE PHOTOGRAPHS
□ GRAY SCALE DOCUMENTS
□ LINES OR MARKS ON ORIGINAL DOCUMENT
□ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.